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Abstract 
BACKGROUND: Wegener’s granulomatosis (WG) is a severe and potentially life-
threatening disease characterized by necrotizing granulomatous vasculitis of small- to 
medium-sized blood vessels. Chemokines are powerful inflammatory mediators, contributing 
to inflammation through attraction of immune cells, and are, consequently, involved in 
several inflammatory and autoimmune disorders, such as rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE). It has never been established, however, whether 
chemokines are also involved in the pathophysiology of WG.  
METHODS: 1) Serum from 14 WG patients and 9 healthy controls was analyzed with respect 
to circulating levels of the CC chemokines monocyte chemoattractant protein (MCP)-1, 
macrophage inflammatory protein (MIP)-1α, and regulated on activation normal T-cell 
expressed and secreted (RANTES), and the CXC chemokines epithelial cell-derived 
neutrophil-activating factor (ENA)-78 and interleukin (IL)-8. 2) Peripheral blood 
mononuclear cells (PBMC) from 9 WG patients and 9 healthy controls were stimulated in 
vitro with staphylococcal enterotoxin B (SEB) and methylprednisolone (MP), and the 
resultant levels of chemokine gene expression and secretion were measured by real-time 
reverse transcriptase – polymerase chain reaction (RT-PCR) and enzyme-linked 
immunosorbent assays (ELISA), respectively.  
RESULTS: 1) The serum levels of MCP-1 and RANTES were significantly elevated in WG 
patients, compared to healthy controls. Moreover, patients with active disease displayed a 
trend for lower RANTES levels and higher ENA-78 levels in the systemic circulation than 
patients in remission. 2) In PBMC from healthy controls all chemokines investigated were 
down-regulated following treatment in vitro with MP, considering both protein and mRNA 
levels. On the other hand, MP-mediated suppression of chemokine secretion from PBMC 
isolated from WG patients was only evident for IL-8, whereas the gene expression of IL-8, 
ENA-78, and RANTES was also down-regulated. While effective in inhibiting elevated levels 
of chemokine secretion following stimulation with SEB, MP failed to counteract the SEB-
induced up-regulation of gene expression, in both WG patients and healthy controls.  
CONCLUSION: The elevated circulatory chemokine levels observed in WG patients and the 
in vitro down-regulation of chemokine levels following treatment with MP in vitro suggest 
that chemokines may indeed be involved in the pathophysiology of Wegener’s 
granulomatosis. 
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1. INTRODUCTION 
1.1 WEGENER’S GRANULOMATOSIS 
Wegener’s granulomatosis (WG) is a severe disease, probably with autoimmune aetiology, 
that may affect as many as 1 in 20,000 people in Norway (1, 2), and at least 1 in 30,000 in the 
United States (3). Although it has a clinical predilection of affecting the upper airways, lungs 
and kidneys, WG is a multi-system disease, and mortality is high without specific therapy.  
1.1.1 Clinical features 
Patients with WG present with a wide variety of symptoms, commonly mimicking other 
disorders. The upper respiratory tract is usually the first site of clinical disease in most 
patients, the typical lung findings being necrotizing vasculitis and focal granulomatous 
inflammation affecting capillaries or medium-sized vessels, or both. Another characteristic of 
WG is the nasal deformity (“saddle nose”) caused by sinusitis and nasal chondritis, which 
may appear early or late in the course of the illness (Fig. 1.1). (4)  
 
The kidneys are also commonly affected in generalized disease, resulting in a focal, 
segmental, thrombotic, and necrotizing glomerulonephritis which progresses to a crescentic 
glomerulonephritis with periglomerular and focal interstitial inflammatory infiltrates. WG 
may also involve joints, skin, peripheral nerves, skeletal muscle, heart, brain and eyes (Fig. 
1.2). (5)  
 
A strict diagnosis of WG depends on 1) characteristic 
clinical signs and symptoms, 2) histological 
demonstration of characteristic features with 
necrotizing granulomatous vasculitis that cannot be 
attributed to infection, and/or 3) compatible clinical 
features and the detection in serum of anti-neutrophil 
cytoplasmic antibodies (ANCAs) that are usually 
specific for the neutrophil-derived cytoplasmic granule 
enzyme proteinase-3 (PR3). The diagnosis should not 
rely on any one of these variables alone. However, 
many patients do not have classical features at disease 
onset, and early manifestations may be diagnosed as 
Figure 1.1: Nasal deformity (“saddle 
nose”) commonly seen in Wegener’s 
granulomatosis patients. Adapted from 
Waheed, 1996. (6)
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sinusitis due to allergy or infection, 
pneumonia, lung cancer or other 
malignancies, rheumatoid and other 
forms of arthritis, or idiopathic 
nephritis. In such cases, the diagnostic 
challenge may be considerable. (5)  
 
 
 
 
 
 
 
 
 
1.1.2 Aetiology and pathogenesis 
WG is a necrotizing, granulomatous vasculitis belonging pathologically to the small- to 
medium-sized vessel systemic vasculitides (7). Like most of the other primary vasculitides, its 
aetiology remains unknown, and the theories dealing with its pathogenesis are currently based 
on circumstantial evidence. For instance, presence of ANCAs directed against neutrophilic 
proteinases correlates with disease activity in the small-vessel vasculitides, and is utilized in 
the diagnosis of WG (8-10). Although their role in the small-vessel vasculitides is supported 
by substantial evidence, the particular role of the ANCAs, that is, whether they are causing 
the disease or resulting from it, and how this is done, is presently a matter of speculation (11). 
 
Furthermore, a number of genetic predispositions have been identified as possible 
determinants of disease occurrence and clinical course. For example, heterozygosity in the 
PiZ allele of the (α1-PI) gene, producing subnormal levels of α1-PI, a protein that is protective 
against the effects of proteolytic enzymes released from leukocytes undergoing degranulation, 
has been shown to correlate with PR3-ANCA-positive vasculitis and may increase the risk of 
Figure 1.2: Clinical features of Wegener’s 
granulomatosis (WG). CNS, central nervous 
system; ANCA, anti-neutrophil cytoplasmic 
antibodies; PR3, proteinase-3; MPO, 
myeloperoxidase. Adapted from Hoffmann 
and Gross, 2002. (4) 
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fatal outcome (5). Predominant involvement of the airways and the presence of neutrophilic 
alveolitis at disease onset have led to speculation that an inhaled agent may trigger the disease 
(4). Moreover, relapses of disease often follow systemic infections, suggesting a role for 
infection in priming neutrophils and activating endothelial cells. Finally, nasal carriage of 
Staphylococcus aureus has been proposed as a risk factor for development of relapse, possibly 
as a result of the actions of staphylococcal superantigens (5). Further elucidation of the 
possible mechanisms underlying WG is required. 
1.1.3 Treatment and prognosis 
As in most of the other systemic vasculitides, aggressive immunosuppressive therapy forms 
the foundation of WG treatment. There are marked variations in presentation, course of 
illness, and tendency for relapse of disease, and treatment is therefore tailored to each patient. 
Daily oral cyclophosphamide (2 mg/kg/day) or high-dose monthly intravenous 
cyclophosphamide (500 mg/m2) in combination with glucocorticoids (1 mg/kg/day) has 
proven the most effective treatment for patients with active WG, and is the treatment of 
choice for inducing remission in critically ill patients (12). This regimen is, however, 
commonly associated with severe side-effects, and is substituted with less toxic maintenance 
therapy regimens as soon as possible. Such regimens include the combination of methotrexate 
and glucocorticoids, which have also proven effective in inducing remission in WG-patients 
(13, 14), and the utilization of other immunosuppressive agents, such as azathioprine or 
cyclosporine, in combination with glucocorticoids, although these regimens have not been 
found to induce remission successfully (12). Regardless of the type of medication employed 
in the alleviation of active WG, tapering of dosage in accordance to clinical improvement is 
recommended because of the inherent toxicity of immunosuppressive drugs. 
 
Although once considered a disease with very high short-term mortality, the introduction of 
effective treatment options, and in particular the introduction of cyclophosphamide, has 
converted WG into a chronic disorder, the most common cause of death now being infections 
secondary to the drug-induced suppression of host defences (15). In chronic illness, as 
compared to life-threatening disease, the acceptable levels of treatment-associated morbidity 
are markedly lowered. There is, therefore, a strong need for new treatment modalities in the 
handling of chronic WG.  
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1.2 CHEMOKINES 
Cytokines are peptides which mediate cell-to-cell interactions via specific cell surface 
receptors and regulate activation, differentiation, growth, death, and acquisition of effector 
functions of immune cells (16). The chemoattractant cytokines, or chemokines for short, 
constitute a class of cytokines with chemoattractant properties, inducing cells that carry the 
appropriate receptors to migrate toward the chemokine source. Chemokines are released by 
many different types of cells, serving to guide cells involved in innate, as well as adaptive, 
immunity (17). 
1.2.1 Classification 
The chemokines are highly basic proteins of 70-125 amino acids with molecular masses 
ranging from 6 to 14 kDa. All chemokines are related in amino acid sequence and display 
similar protein structures. Based on the configuration of a pair of intramolecular disulfide 
bridges, they are assigned to one of two major groups: CC (α-) chemokines, in which the 
cysteines engaged in bridge formation are adjacent, and CXC (β-) chemokines, in which the 
equivalent two cysteine residues are separated by another amino acid. In addition, there has 
been found one C (γ-) chemokine – lymphotactin – which has only one disulfide bridge, and 
one CX3C (δ-) chemokine – fractalkine – where the bridge-forming cysteines enclose three 
amino acids (Fig. 1.3). The CXC chemokines can be divided further by the presence or 
absence of an amino acid triplet (ELR; glutamic acid − leucine − arginine) preceding the first 
of the invariant cysteines. All the CXC chemokines that attract neutrophils have this motif, 
while the other chemokines lack it. The ELR-motif is also distinctive for the chemokines 
entailing angiogenic properties. (18, 19)  
 
Figure 1.3: Structural characteristics of the chemokine subclasses. Fractalkine (CX3CL) is currently the only 
chemokine known to be membrane-bound. Adapted from Bajetto et al., 2002. (20)  
 
A new chemokine nomenclature is presently being implemented world-wide, providing each 
of the 50 chemokines detected so far with systematic names based on its structural 
characteristics (21). However, in this thesis all chemokines are referred to primarily by their 
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original names. A complete list of chemokines (anno 2000) with both new and old names can 
be found in the Appendix, Table 1. 
1.2.2 Chemokine receptors 
The chemokine receptors are G-protein-linked integral membrane proteins containing seven 
membrane-spanning helices. CC and CXC chemokines act on different groups of receptors 
designated CC and CXC receptors, respectively. Each chemokine may bind and interact with 
one or more receptors within the matching receptor subgroup, and vice versa. The distribution 
of receptors thus determines the subset of cells on which each chemokine may exert its 
effects. (18) For a complete outline on the redundancy of chemokine – chemokine-receptor 
interactions the reader is referred to the Appendix, Table 1. 
 
The effects of chemokine ligation are mediated through several intracellular signalling 
pathways, mainly originating from the activation of G-protein. The main signal transduction 
pathways are depicted in Fig. 1.4. 
 
 
Figure 1.4: Schematic presentation of the main 
signal transduction pathways activated by 
chemokines. AC, adenylyl cyclase; JAK, janus 
activated kinase; STAT, signal transducer and 
activator of transcription; α, β, γ, subunits of G-
protein; PLC, phospholipase C; FAK, focal 
adhesion kinase; PYK2, protein tyrosine kinase 2; 
PI3K, phosphoinositide 3-kinase; ERK 
extracellular signal-regulated kinase; AKT, 
protein kinase B. Red arrows indicate pathways 
mediated by α subunits of G-proteins, blue 
arrows by the βγ-complex. Adapted from Bajetto 
et al., 2002. (20) 
1.2.3 Biological functions of chemokines 
The primary chemokine functions are chemoattraction of leukocytes to sites of inflammation 
and tissue injury, and activation of leukocyte effector functions at arrival to these sites (Fig. 
1.5). Chemoattraction of immune cells is a property shared by the entire chemokine family, 
resulting from the receptor-mediated modulation of actin-dependent cell propagation and up-
regulation of adhesion proteins. Several chemokines, such as interleukin (IL)-8 and monocyte 
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chemoattractant protein (MCP)-1, trigger integrin-dependent firm adhesion of rolling cells, an 
important step in the trafficking of leukocytes to sites of inflammation (22). Some 
chemokines also serve to activate effector functions of both leukocytes and resident tissue 
cells. For instance, certain CC chemokines, including MCP-1, macrophage inflammatory 
protein (MIP)-1α, regulated on activation normal T-cell expressed and secreted (RANTES) 
and eotaxin, can mediate allergic reactions and increase oxidative stress by inducing the 
release of histamine and reactive oxygen species from eosinophils, mast cells, and basophils 
(19, 23). Furthermore, some chemokines, such as MIP-3β, 6 cysteine chemokine (6Ckine), 
and B-cell-activating chemokine (BCA)-1 are critical for the development of secondary 
lymphoid tissues in mice (17), whereas others, the CXC-chemokines in particular (e.g., 
stromal cell-derived factor (SDF)-1), have been found to have important functions in 
angiogenesis and organ development (24). Thus, many pivotal roles of chemokines, not only 
confined to orchestration of immune responses, have been characterized. However, the 
chemokine network and its extensive applications are far from fully elucidated. 
 
Figure 1.5: Chemokine regulation of leukocyte movement. Chemokines (red dots) are secreted at sites of 
inflammation and infection by resident tissue cells, resident and recruited leukocytes, and cytokine-activated 
endothelial cells. 1) Leukocytes rolling on the endothelium in a selectin-mediated process are brought into 
contact with chemokines retained on cell surface heparin sulphate proteoglycans. 2) Chemokine signalling 
activates leukocyte integrins, leading to 3) firm adhesion and 4) extravasation. 5) The leukocytes follow the 
chemokine gradient to the source of chemokine secretion, and 6) initiate effector functions. 
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1.2.4 Chemokines in disease 
Chemokines are associated with a number of diseases, ranging from atherosclerosis to 
acquired immune deficiency syndrome (AIDS) (25). The malarial parasite Plasmodium vivax 
is known to utilize the Duffy antigen receptor for chemokines (DARC), which is a chemokine 
binding protein that binds both CC and CXC chemokines with equal affinity, as a portal of 
entry into human erythrocytes. Furthermore, the chemokine receptors CCR5 and CXCR4 are 
involved in the pathogenesis of AIDS, as they are employed by the human immunodeficiency 
virus (HIV)-1 to promote cellular fusion and infection. Other viruses, including members of 
the herpes and poxvirus classes, have pirated chemokine receptors from their hosts, 
presumably to help them overcome the immune response. (17)  
 
Chemokines have also been linked to several autoimmune disorders, such as multiple 
sclerosis (MS) and rheumatoid arthritis (RA). Moreover, a role for chemokines has been 
suggested in coronary heart disease, asthma, and organ transplant rejection (25-27). Given 
their important role in orchestrating responses of the immune system, it is not surprising that 
dysregulation of the chemokine network may lead to dysfunction of the immune apparatus 
and, ultimately, disease. Based on the potential role of chemokines in the pathophysiology of 
a number of diseases, several chemokine receptor antagonists are presently being investigated 
for therapeutic properties. (28)  
1.2.5 Chemokines in Wegener's granulomatosis 
The role of chemokines in inflammation suggests that they may also be involved in WG, 
which is, in fact, characterized by inflammation and necrosis of blood-vessel walls. This 
assumption is sustained by several experimental findings, including the observations that 
production of RANTES in pulmonary WG lesions is elevated (29) and that the expression of 
IL-8 in monocytes is induced by ANCAs, which are believed to be influential in the 
development and exacerbation of this disease (30). PR3, the major antigen of WG-associated 
ANCAs, has been shown to enhance endothelial-cell production of IL-8 and MCP-1 (31). 
Furthermore, a number of studies have shown the presence of chemokines specific for 
neutrophils (IL-8) (32) and mononuclear cell subsets (MCP-1, RANTES, MIP-1α, MIP-1β) 
(33, 34) in renal biopsies from patients with WG. Although these findings are indicative of a 
role for chemokines in WG, additional investigations are required to further elucidate their 
implication. In particular, few studies have examined the effects of immunosuppressive 
medication on the chemokine network. 
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1.3 GLUCOCORTICOIDS 
Glucocorticoids (GCs) are employed in the therapy of a wide spectre of disorders, mostly 
characterized by inappropriate immune responses or autoimmunity. These include, amongst 
others, allergic disorders, asthma, autoimmune and inflammatory disorders, cancer, and organ 
transplantation (35). In most cases, systemic GC therapy is highly effective in ameliorating 
disease symptoms and activity. However, the actions of GCs are mediated through receptors 
found in almost every cell of the body, resulting in powerful and widespread effects, and 
commencing not only therapeutic, but also toxic responses. 
1.3.1 Clinical aspects 
The endogenous glucocorticoids belong to a group of hormones collectively known as the 
corticosteroids. The corticosteroids are categorized as glucocorticoids, affecting intermediary 
metabolism, inflammation, immunity, wound healing, myocardial and muscle integrity, or 
mineralocorticoids, regulating salt, water, and mineral metabolisms. However, most 
corticosteroids, both endogenous and synthetic, produce a combination of both glucocorticoid 
and mineralocorticoid effects. (36)  
 
The adverse effects commonly accompanying 
systemic GC therapy (Table 1.1) may sometimes 
represent a limiting factor to the treatment, especially 
when treatment is not life-saving. When the aims of 
therapy are confined to relieving symptoms, severe 
treatment-associated morbidity is unacceptable, calling 
for cessation of treatment or implementation of less 
toxic regimens, such as alternate day dosage 
(preferably in the morning, to comply with the 
endogenous diurnal rhythm of hormone secretion) or 
local/compartmental administration (e.g., topical or 
intra-articular). The concurrent administration of other 
immunosuppressants (so-called “steroid-sparing” 
agents), such as azathioprine, methotrexate, and 
cyclosporine, may allow for a reduction in GC-dose, 
thus reducing overall toxicity. (38)  
Very common side effects: 
Weight gain  
Mood swings 
Common side effects: 
Mild weakness in limbs  
Easy bruising of skin  
Impaired wound healing  
Acne  
‘Moon face’ 
Slowed growth in children and 
adolescents  
Osteoporosis 
Cataracts 
Immunosuppression  
Hypothalamic-pituitary-adrenal axis 
suppression  
Occasional side effects: 
High blood pressure  
Elevated blood sugar, worsening of 
diabetes mellitus 
Red/purple stretch marks 
Stomach irritation, ulcers 
 
 
Table 1.1: Side effects of systemic 
glucocorticoid (GC) therapy. Adapted 
from Matsen (2002). (37) 
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Due to the negative feedback imposed by high levels of circulatory GCs on the hypothalamic-
pituitary-adrenal axis, the endogenous production of corticosteroids is commonly down-
regulated during systemic GC treatment. Furthermore, long-term treatment with GCs is 
associated with down-regulation of glucocorticoid receptor (GR), and, moreover, decreased 
function of other genes that are GC-sensitive (39). Owing to this suppression of the normal 
regulation of GC activity, abrupt termination of GC treatment must be avoided. Instead, a 
gradual tapering of dosage, including implementation of alternate-day dosing regimens, is 
recommended (35). 
1.3.2 Cellular effects 
The powerful immunosuppressive actions of GCs are the result of a variety of cellular effects. 
These include inhibition of chemotaxis and bactericidal activity in neutrophils and monocytes, 
lymphopenia, decreased macrophage function, and disturbed complement activation. The GCs 
reduce the number of circulating immune cells through apoptosis and redistribution, and 
restrain several of their functions, such as cytokine-release. The sum of these effects is 
impaired inflammatory function of immune cells, resulting in reduced immune activity and 
alleviation of inflammation, thus producing the principal effects of GC treatment. (38, 40)  
1.3.3 Mechanisms of action 
Most of the effects of GCs are thought to be mediated via the cytoplasmic GR (Fig. 1.6). The 
non-activated GR resides in the cytosol in the form of a hetero-oligomer with other highly 
conserved proteins, including heat-shock proteins (HSPs) and immunophilin. Upon binding of 
GC, which is facilitated through interaction with HSP 90, the GR dissociates from the rest of 
the hetero-oligomer and translocates into the nucleus. Before or after the translocation, the 
receptor forms homodimers. Inside the nucleus, the hormone-receptor complexes bind to 
specific DNA sequences called “GC responsive elements” (GREs), with ensuing inhibition or 
enhanced transcription of the associated genes. (38, 41)  
 
One major way of GC-mediated gene suppression is through interaction of the hormone-
receptor (GC-GR) complex with the c-Jun/c-Fos heterodimer, which binds to the activating 
protein (AP)-1 site of genes of several growth factors and cytokines. The GC-GR complex 
prevents the c-Jun/c-Fos heterodimer from stimulating the transcription of these genes. Cross-
talk between the GC-GR complex and other transcription factors is further exemplified by its 
interaction with nuclear factor (NF)-κB, which is known to regulate several important 
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inflammatory mediators, including the chemokines IL-8, MCP-1, and RANTES, and which 
may contribute significantly to the GC resistance discussed later. Furthermore, the GC-GR 
complexes may also act by inducing transcription of certain mRNases, thereby indirectly 
reducing the stability of their respective substrate mRNA. All these mechanisms are 
collectively termed “genomic” mechanisms, as they directly or indirectly affect gene 
transcription. (38, 41)  
 
 
Figure 1.6: Mechanisms of action for the genomic glucocorticoid signalling pathway. Steroid hormone (S) 
circulates as a free molecule or as a complex with plasma-binding protein. After the steroid enters the cell, it 
binds to receptors (R) that reside in the cytosol complexed to heat-shock protein (HSP) and immunophilin (IP). 
Binding of the ligand to the complex causes dissociation of HSP and IP. The receptor-ligand translocates into the 
nucleus where it binds at or near the 5’-flanking DNA sequences of certain genes (glucocorticoid responsive 
elements (GRE)). Receptor binding to the regulatory sequences of the responsive genes increases or decreases 
their expression – illustrated by ON and OFF, respectively. Glucocorticoids may also exert their effects post-
transcriptionally by either increasing the degradation of messenger RNA (mRNA) or by inhibiting the synthesis 
or secretion of the protein. AP, activating protein; DNA, deoxyribonucleic acid; RNA, ribonucleic acid. Adapted 
from Boumpas et al., 1993 (38). 
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In addition to the genomic mechanisms, some of the effects of GCs may also be mediated 
through so-called “non-genomic” mechanisms, which operate independently of gene 
transcription (Fig. 1.7).  
 
Figure 1.7: Schematic presentation of non-genomic binding sites of glucocorticoids (GCs). The closed triangle 
represents the GC molecule. The following mediators of non-genomic GC effects have been identified so far: 1) 
ion channels (e.g. the synaptic voltage-dependent calcium channel); 2) neurotransmitter receptors (e.g. the 
acetylcholine and the kappa opioid receptors); 3) specific, non-genomic membrane receptors (that may still 
represent a protein with other functions); 4) modified membrane GC receptors (GRs) (although genomically 
active, data suggest that these modified GRs may mediate non-genomic effects as well); 5) active proteins 
released from the GR complex upon binding the ligand. 6) Represents the classical, genomic way of action. 
Adapted from Makara and Haller, 2001. (42) 
 
The non-genomic mechanisms are characterized by a rapid response (seconds/minutes), and 
are otherwise distinguished from the genomic mechanisms by 1) independency of 
corticosteroid receptors (including both the mineralocorticoid (MR) and glucocorticoid (GR) 
receptors), and 2) ability to execute their actions in the absence of a genomic apparatus (42). 
1.3.4 Glucocorticoid effects on chemokines 
The expression of many pro-inflammatory chemokines, including IL-8, MIP-1β, MIP-3β, 
MCP-1, MCP-2, MCP-3, thymus- and activation-related chemokine (TARC), and eotaxin, is 
down-regulated in response to GC therapy (43). Other GC-regulated chemokines are 
RANTES, MIP-1α, and MCP-1 (44). Although GCs also affect other pro- and anti-
inflammatory mediators in a similar fashion, the modulation of chemokines is believed to 
contribute markedly to the effects of this class of drugs (31, 43). 
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1.3.5 Glucocorticoid resistance 
Although GCs support and regulate several physiological functions that are essential to life, 
there are considerable inter-individual variations in GC responsiveness (45), and up to 30 % 
of the normal population may be unresponsive to anti-inflammatory GC treatment, as 
suggested in a study of lymphocyte steroid sensitivity in healthy volunteers (46). GC 
treatment is one of the factors that may contribute to GC resistance, but the underlying 
mechanisms for this phenomenon are largely unknown. However, some proposed 
mechanisms include (Fig. 1.8): 1) reduction in total GC binding sites through homologous 
down-regulation (39); 2) Up-regulation of the levels of β-type GR (GRβ), which is formed by 
an alternative splicing of the GR pre-mRNA and functions as an endogenous inhibitor of the 
genomically active α-type GR (47); 3) NF-κB-mediated trans-repression of the transcriptional 
activities of GR (45). GC resistance may interfere severely with the effects of GC therapy, 
necessitating the introduction of more powerful, but also more toxic, agents in the 
management of inflammatory diseases. 
 
Figure 1.8: Mechanisms of glucocorticoid resistance.  NF, nuclear factor; AP, activating protein; GRE, 
glucocorticoid responsive element; hGR, human glucocorticoid receptor; HSP, heat-shock protein Adapted 
from Schaaf and Cidlowski, 2002 (45). 
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1.3.6 Glucocorticoids in the management of Wegener’s granulomatosis 
The GCs have played a central role in the treatment of WG since their introduction in this 
condition some 40 years ago. They alleviate effectively the detrimental effects of the vascular 
inflammation associated with WG, and have a central position in inducing disease remission. 
However, their effects are widespread and pleomorphic, and the exact mechanisms underlying 
their therapeutic properties in WG remain uncertain, although the down-regulation of pro-
inflammatory mediators most likely plays a role. (43)  
 
As mentioned above, GCs are commonly co-administered with other immunosuppressive 
agents, such as cyclophosphamide, azathioprine or methotrexate. Although the current 
regimens relatively effectively induce and sustain disease remission, a majority of the patients 
experience relapses. In particular, several investigations have demonstrated an unacceptably 
high relapse rate in the course of tapering corticosteroids and/or decreasing the frequency of 
cyclophosphamide administration to less than once monthly. Another shortcoming of the 
current therapy is the presence of a considerable level of treatment-related morbidity. 
Considerable effort is therefore made to develop improved immunosuppressive drugs, and 
there are several studies in progress exploring the utility of biological agents that may have 
both precise immunoregulatory effects and diminished toxic properties. (4)  
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1.4 AIMS OF THE STUDY 
 
The aims of the present study are to:  
 
1. Investigate the role of chemokines in the pathogenesis of Wegener’s 
granulomatosis 
 
2. Identify effects of glucocorticoid therapy on the chemokine network that may 
possibly be of importance to its therapeutic efficacy 
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2. MATERIALS AND METHODS 
2.1 PATIENTS AND CONTROLS 
All patients included in our studies fulfilled the American College of Rheumatology 1990 
classification criteria and the Chapel Hill Consensus Conference on the Nomenclature of 
Systemic Vasculitis 1992 definition of WG (48, 49). WG patients were classified as having 
active disease or being in remission based on clinical judgement, the Birmingham Vasculitis 
Activity Score (BVAS) (48), and levels of C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR). Signed informed consent was obtained from each individual. Our 
investigations conform to the principles outlined in the Declaration of Helsinki (50). 
 
Patients and controls were included for two separate part studies. The first study population, 
which consisted of 14 patients with WG and 9 healthy controls, were included for 
measurement of serum chemokine levels. Demographic and clinical data are given in table 2.1 
and 2.3, respectively. 
 
Table 2.1: Fourteen patients with Wegener’s granulomatosis were included in the study of serum chemokine 
levels. Seven were suffering active disease at the time of blood-sampling, whereas the rest were in remission. 
No. Sex Age (years) Disease activity ESR (mm/h) CRP (mg/l) Medication 
#1 Female 21 Remission n.d. <5 PRE (10 mg) 
#2 Male 33 Remission 18 5 PRE (20 mg) 
#3 Female 29 Remission 10 <5 Trim-Sulpha (160+800 mg) 
#4 Male 54 Active 47 16 CYC (110 mg) 
PRE (25 mg) 
#5 Male 65 Remission 11 <5 PRE (20 mg) 
#6 Male 59 Remission 17 <5 Trim-Sulpha (160+800 mg) 
#7 Male 60 Active 34 11 PRE (20 mg) 
#8 Male 23 Active 61 29 CYC (150 mg) 
PRE (15 mg) 
#9 Male 36 Active >100 161 PRE (7.5 mg) 
Trim-Sulpha (160+800 mg) 
#10 Female 78 Active 21 13 PRE (10 mg) 
#11 Female 35 Remission 110 14 None 
#12 Female 54 Active 96 62 CYC (250 mg) 
PRE (20 mg) 
#13 Female 52 Remission 8 57 None 
#14 Female 25 Active 28 62 CYC (250 mg) 
PRE (20 mg) 
 
 
Medication is expressed in terms of daily dosage. AZA, azathioprine; CYC, cyclophosphamide; PRE,
prednisolone; Trim-Sulpha, trimethoprim-sulphametoxazol; n.d., not determined; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein. 
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From the second study population, consisting of 9 WG patients and 9 age- and sex-matched 
healthy controls, peripheral blood mononuclear cells (PBMC) were isolated (see chapter 2.2) 
for analysis in vitro. Demographic and clinical data on this population are given in tables 2.2 
and 2.3. 
 
Table 2.2: Patients with Wegener’s granulomatosis that were included in the second study, conserning 
chemokine levels in vitro. Four of the patients were suffering active disease at the time of blood-sampling.  
No. Sex Age (years) Disease activity ESR (mm/h) CRP (mg/l) Medication 
#1 Male 20 Remission 7 <5 AZA (150 mg) 
PRE (5 mg) 
Trim-Sulpha (320+1600 mg) 
#2 Female 33 Remission 7 <5 MTX (15 mg weekly) 
PRE (10 mg) 
Trim-Sulpha (160+800 mg) 
#3 Male 62 Remission 13 <5 IvIg (40 g monthly) 
#4 Female 31 Remission 26 8 IvIg (30 g monthly) 
PRE (5 mg) 
#5 Male 38 Active 49 13 Trim-Sulpha (320+1600 mg) 
#6 Female 72 Active 64 97 Trim-Sulpha (160+800 mg) 
PRE (30 mg) 
#7 Male 38 Active 18 26 IvIg (25 g monthly) 
PRE (25 mg) 
#8 Female 60 Active 28 16 IvIg (40 g monthly) 
PRE (5 mg) 
Trim-Sulpha (160+800 mg) 
#9 Male 26 Remission 5 <5 PRE (20 mg) 
Trim-Sulpha (160+800 mg) 
Medication is expressed in terms of daily dosage, unless stated differently. AZA, azathioprine; PRE, 
prednisolone; Trim-Sulpha, trimethoprim-sulphametoxazol; IvIg, intravenous immunoglobulin infusion; MTX, 
methotrexate. 
 
 
 
 
 
 
 
Serum study In vitro study No. Age (yrs) Sex Age (yrs) Sex 
#1 33 Male 23 Male 
#2 42 Male 34 Female 
#3 24 Female 59 Male 
#4 64 Female 31 Female 
#5 54 Male 37 Male 
#6 47 Female 64 Female 
#7 27 Female 34 Male 
#8 50 Male 55 Female 
#9 47 Male 25 Male 
Table 2.3:  Characteristics 
of the healthy controls 
included in the present 
studies. In the in vitro
study, healthy controls 
were matched to WG
patients with respect to age 
and sex in order to 
eliminate sex- and age-
related bias.  
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2.2 ISOLATION OF PBMC 
Materials 
- Heparinized whole blood (Rikshospitalet University Hospital, Norway) 
- Lymphoprep™ (Axis-Shield PoC AS, Norway; prod.no: 1053980) 
- Sodium chloride solution, 9 mg/ml (B. Braun Melsungen AG, Germany) 
- RPMI 1640 with HEPES (PAA Laboratories GmbH, Austria; cat.no: E15-842) 
- Staining solution for the counting of leukocytes (NMD AS, Norway; cat.no: 327395) 
- Labolux 11 100x microscope (Leitz Wetzlar AG, Germany) 
- Assistent™ Bürker counting chamber (Karl Hecht KG, Germany) 
- Centrifuge with cooler (Megafuge™ 1,0R; Heraeus Sepatech GmbH, Germany) 
- LS 4800 nitrogen tank (Taylor-Wharton-Cryogenics Inc., Alabama, USA) 
Method 
Peripheral venous blood was drawn into pyrogen-free tubes with heparin as anticoagulant. 
PBMC were isolated within 45 minutes of respite in room temperature.  
 
PBMC were isolated using Isopaque-Ficoll (Lymphoprep™) density gradient centrifugation. 
The density of Isopaque-Ficoll is lower than that of erythrocytes and granulocytes, and greater 
than that of lymphocytes and monocytes, collectively designated PBMC. During 
centrifugation, therefore, the erythrocytes and granulocytes will form a pellet in the bottom of 
the centrifugation tube, whereas the PBMC will form a layer on the interface between the 
Isopaque-Ficoll and medium layers.  
 
Whole blood was diluted 1:1 with 9 mg/ml NaCl aquatic solution in a 50 ml centrifugation 
tube. Isopaque-Ficoll was carefully layered at the bottom of the tube, and the tube was 
centrifuged at 500 × g for 25 minutes at 20 °C with minimum brake. The PBMC layer was 
collected and centrifuged at 650 × g for 15 minutes at 4 °C. The pellet was resuspended and 
washed twice in RPMI 1640 with HEPES (N-[2-Hydroxyethyl] piperazine-N'-[2-
ethanesulfonic acid]), followed by centrifugation at 650 × g for 10 minutes at 4 °C. Finally, 
the resulting pellet of isolated PBMC was resuspended in RPMI, and the concentration and 
total amount of cells were assessed using a Bürker counting chamber. 
 
PBMC isolated from whole blood were resuspended in RPMI 1640 with HEPES and 
distributed into Nunc-tubes in appropriate volumes (equivalent to approximately 12 × 106 
cells). The tubes were centrifuged at 650 × g for 10 minutes at 4 °C and, after discarding of 
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the supernatant, the pellets were stored in liquid nitrogen for subsequent RNA isolation and 
gene expression analysis (by real-time RT-PCR, see chapter 2.8). 
2.3 PREPARATION OF PLASMA AND SERUM 
2.3.1 Preparation of serum 
Materials 
- Whole blood (Rikshospitalet University Hospital, Norway) 
- Centrifuge with cooler (Megafuge™ 1.0R; Heraeus Sepatech GmbH, Germany) 
- Ultra-freezer, -80 °C (Forma Scientific Inc., Ohio, USA) 
Method 
Whole blood drawn in collecting-tubes with no additive was put on ice for 1.5 hours to 
coagulate. The tube was then centrifuged at 1300 × g for 10 minutes at 4 °C. Serum was 
partitioned into several Nunc-tubes and stored in a -80 °C freezer. 
2.3.2 Preparation of plasma 
Materials 
- Whole blood (Rikshospitalet University Hospital, Norway) 
- Centrifuge with cooler (Megafuge™ 1.0R; Heraeus Sepatech GmbH, Germany) 
- Ultra-freezer, -80 °C (Forma Scientific Inc., Ohio, USA) 
Methods 
Whole blood was collected in tubes containing ethylenediaminetetraacetic acid (EDTA) in 
order to prevent coagulation. The blood samples were subjected to centrifugation (1300 × g 
for 10 minutes at 4 °C) within 30 minutes. Plasma was partitioned into Nunc-tubes and stored 
in a -80 °C freezer. 
2.4 IN VITRO EXPERIMENTS 
PBMC were cultured and activated in vitro in order to investigate the cellular effects of an 
experimentally induced immune activation and its alleviation with MP. Culturing of PBMC 
was performed through re-suspension of the cells in culture medium, and required no pre-
treatment other than the separation from whole blood depicted above (chapter 2.2). A mixture 
of 5 % foetal calf serum (FCS) in RPMI with HEPES is suitable as culture medium for 
sustaining viable cultures of PBMC. Experimental immune activation was induced by 
addition of staphylococcal enterotoxin B (SEB). 
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2.4.1 Staphylococcal enterotoxin B 
SEB belongs to a class of pathogens known as superantigens (SAgs). SAgs are a class of 
bacterial and viral proteins exhibiting highly potent lymphocyte-transforming (mitogenic) 
activity towards human and/or other mammalian T lymphocytes. Unlike conventional 
antigens, SAgs bind to certain regions of major histocompatibility complex (MHC) class II 
molecules of antigen-presenting cells (APCs) outside the classical antigen-binding groove and 
concomitantly bind in their native form to T cells at specific motifs of the variable region of 
the β chain (Vβ) of the T-cell receptor (TCR) (Fig. 2.1). This interaction triggers the 
activation (proliferation) of the targeted T lymphocytes and leads to the in vivo or in vitro 
release of large amounts of various cytokines and other effector substances by immune cells. 
The human T-cell repertoire comprises about 24 major types of Vβ elements. Any SAg binds 
specifically to a characteristic set of receptor sequences, and may bind to several distinct Vβ 
elements. As a consequence, SAgs stimulate at nano- to picogram concentrations up to 30 % 
of T cells while only 1 in 105-106 T cells are activated upon conventional antigenic peptide 
presentation to the TCR in the immune response. (51)  
 
As mentioned previously, chronic nasal carriage of Staphylococcus aureus constitutes a risk 
factor for the development of exacerbations in WG. Circulating T cells of WG patients are 
persistently activated, suggesting the presence of chronic stimulus. A causal link between 
chronic carriage of S. aureus and chronic T-cell 
activation in WG is conceivable, because S. aureus 
produces SAgs, which are potent T-cell 
stimulators. (52)  
 
 
 
 
 
 
 
 
 
Figure 2.1: Model of T-cell activation by a conventional 
peptide antigen (Ag) or by a superantigen toxin (SAg). TCR, 
T-cell receptor; APC, antigen-presenting cell; MHC II, major 
histocompatibility class II complex molecule. Adapted from 
Müller-Alouf et al., 2001. (51) 
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2.4.2 Harvesting of cells and supernatant 
Materials 
- Centrifuge with cooler (Megafuge™ 1,0R; Heraeus Sepatech GmbH, Germany) 
- Cell scrapers (Costar®, New York, USA; cat. no: 3010) 
- Dulbecco’s™ phosphate buffered saline (PAA Labs GmbH, Austria; cat.no: H15-001) 
- LS 4800 nitrogen tank (Taylor-Wharton-Cryogenics Inc., Alabama, USA) 
Method 
Following centrifugation at 450 × g and 4 °C for 5 minutes, the supernatant was collected by 
carefully pipetting from the top of the wells, thereby avoiding cell contamination, and stored 
in Nunc-tubes in a -80 °C freezer. The cells were subsequently detached from the surface with 
a cell scrape, washed twice with ice-cold phosphate-buffered saline (PBS), and transferred to 
Nunc-tubes which were immediately put on ice in order to halt cell metabolism. The Nunc-
tubes were centrifuged at 1800 × g for 10 minutes at 4 °C, and the supernatant was discarded. 
Then the pellets were snap frozen in liquid nitrogen and stored at -80 °C while awaiting 
further preparation and analysis. 
2.4.3 Pilot study I 
Materials 
- Whole blood (Rikshospitalet University Hospital, Norway) 
- Culture medium:  
 · 5 % FCS (TCS BioSciences Ltd., UK; cat.no: CF018) 
 · RPMI with HEPES (PAA Lab. GmbH, Austria; cat.no: E15-842) 
- 6α-Methylprednisolone 21-hemisuccinate sodium (Sigma-Aldrich; cat.no: M 3781) 
- Staphylococcal enterotoxin B (Sigma-Aldrich Co., St. Louis, USA; cat.no: S 4881) 
- Incubator (Forma Scientific Inc., Ohio, USA) 
- 96 well cell culture plates (Costar®, New York, USA; cat.no: 3596) 
- Centrifuge with cooler (Megafuge™ 1.0R; Heraeus Sepatech GmbH, Germany) 
Method 
PBMC were isolated from whole blood by Isopaque-Ficoll density gradient centrifugation 
(described in chapter 2.2) of single blood samples from 2 patients with Wegener’s 
granulomatosis and 1 healthy control and resuspended in culture medium to a cell 
concentration of 2 × 106 cells/ml. The resulting cell culture was partitioned into a culture plate 
and stimulated or not with staphylococcal enterotoxin B (SEB) or methylprednisolone (MP) 
or both. Three different concentrations of SEB (0.01 ng/ml, 1 ng/ml, and 100 ng/ml) and MP 
(10-8 M, 10-7 M, and 10-6 M) were used in order to assess a possible dose-response 
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relationship. In addition, the stimulants were added either before (-1 hour), concurrent, or 
after (+1 hour) in order to assess possible effects of contiguous administration. The plate was 
incubated for 24 hours at 37 °C and 5 % CO2. After incubation, the plate was centrifuged at 
450 × g and 4 °C for 5 minutes. The supernatants were harvested and stored in Nunc-tubes at 
-80 °C. 
2.4.4 Pilot study II 
Materials 
- Whole blood (Rikshospitalet University Hospital, Norway) 
- Culture medium:  
 · 5 % FCS (TCS BioSciences Ltd., UK; cat.no: CF018) 
 · RPMI with HEPES (PAA Lab. GmbH, Austria; cat.no: E15-842) 
- 6α-Methylprednisolone 21-hemisuccinate sodium (Sigma-Aldrich; cat.no: M 3781) 
- Staphylococcal enterotoxin B (Sigma-Aldrich Co., St. Louis, USA; cat.no: S 4881) 
- Incubator (Forma Scientific Inc., Ohio, USA) 
- 24 well cell culture plates (Costar®, New York, USA; cat.no: 3596) 
- Cell scrapers (Costar®, New York, USA; cat.no: 3010) 
- Centrifuge with cooler (Megafuge™ 1.0R; Heraeus Sepatech GmbH, Germany) 
Method 
This study was conducted in order to assess temporal variations in the expression of 
inflammatory chemokines following stimulation with SEB and MP. PBMC were isolated 
from whole blood from one healthy control and resuspended in culture medium to a cell 
concentration of 2 × 106 cells/ml. The resulting cell culture was partitioned into four culture 
plates and stimulated or not with 1 ng/ml SEB or 10-6 M MP or both (added contiguously), as 
determined in the first pilot study (see Results, chapter 3.2.1). The plates were subsequently 
incubated for 6, 8, 12, and 24 hours, respectively, at 37 °C and 5 % CO2. After incubation, 
cells and supernatants were collected as described in chapter 2.4.2. 
2.4.5 Experimental modulation of the production and secretion of chemokines 
in PBMC 
Materials 
Equal to pilot study II. 
Method 
PBMC were isolated from whole blood by Isopaque-Ficoll density gradient centrifugation 
(described in chapter 2.2) of single blood samples from 9 patients with WG (Table 2.2) and 9 
healthy controls (Table 2.3). The cells were subsequently resuspended in culture medium to a 
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cell concentration of 2 × 106 cells/ml. The resulting cell culture was partitioned into a culture 
plate and stimulated or not with 1 ng/ml SEB or 10-6 M MP or both, as determined in the first 
pilot study. The plates were incubated for 6 or 24 hours at 37 °C and 5 % CO2, based on the 
findings of the second pilot study (see Results, chapter 3.2.2). After incubation, cells and 
supernatant was collected as described in chapter 2.5.2. 
2.5 ISOLATION OF RNA 
RNA was isolated from PBMC pellets using the RNeasy® mini kit according to the 
manufacturer’s instructions. In general, frozen samples are disrupted in buffer containing 
guanidine isothiocyanate and homogenized. Ethanol is subsequently added to the lysate, 
creating conditions that promote selective binding of RNA to the RNeasy silica-gel 
membrane. The sample is then applied to the RNeasy mini column. Total RNA binds to the 
membrane, while contaminants are washed away in the sequential washing steps, and total 
RNA is eluted by addition of water.  
Materials 
- RNeasy® Mini Kit (Qiagen™, Maryland, USA; cat.no: 74104) 
- RNA Storage Solution (Ambion® Inc., Texas, USA; cat.no: 7000) 
- Diax 100™ rotor-stator homogenizer (Heidolph Instruments AG, Germany) 
- β-mercaptoethanol (Sigma-Aldrich Co., St. Louis, USA; cat.no: M 6250) 
- 100 % ethanol (Arcus AS, Norway) 
- RNase-free water (Ambion® Inc., Texas, USA; cat.no: 9937) 
- Sodium acetate anhydrous (Sigma-Aldrich Co., St. Louis, USA; cat.no: S 2889) 
- Linear acrylamide (Ambion® Inc., Texas, USA; cat.no: 9520) 
Method 
The following protocol was employed for pellets containing less than 5 × 106 cells. All 
binding, washing, and elution steps were performed by centrifugation in a microcentrifuge. 
Frozen pellets were dissolved, and the cells disrupted, in 350 µl Buffer RLT (lysis buffer 
containing β-mercaptoethanol and guanidine), followed by homogenisation with a rotor-stator 
homogenizer. One volume (350 µl) of 70 % ethanol (100 % ethanol diluted in distilled water) 
was added to the homogenized lysate, which was subsequently filtered on an RNeasy mini 
column placed in a 2 ml collection tube. For pellets containing more than 5 × 106 cells, the 
required volumes of Buffer RLT and 70 % ethanol were 600 µl. Filtration was forced by high-
speed centrifugation (15 s at ≥8000 × g). The column was washed by the sequential addition 
of 700 µl Buffer RW1 (washing buffer containing guanidine) and two additions of 500 µl 
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Buffer RPE (washing buffer). Each addition was followed by a high-speed centrifugation, the 
last centrifugation (following the second addition of Buffer RPE) lasting for 2 minutes to 
make sure that the column’s silica-gel membrane was completely dried. Subsequently, 50 µl 
of RNase-free water was added to the column, and the RNA was eluted by high-speed 
centrifugation. This step was repeated once, the last centrifugation lasting for 1 minute to 
ensure complete elution. 
 
RNA was precipitated with the addition of 2.5 volumes (250 µl) ice-cold 100 % ethanol, 1/10 
volume (10 µl) of a 3 M aqueous solution of sodium acetate and 4 µl linear acrylamide, 
followed by incubation in a -80 °C freezer for at least 1 hour. Afterwards, the RNA 
suspension was centrifuged at maximum speed (≥8.000 × g) and 4 °C for 30-60 minutes. The 
supernatant was discarded, and the pellet was washed with 300 µl 70 % ethanol. After another 
15-30 minutes of high-speed centrifugation in 4 °C, the supernatant was thoroughly removed, 
and the pellet was dissolved in 10 µl RNA Storage Solution. RNA was stored at -80 °C while 
awaiting further analysis. 
2.6 CONCENTRATION AND INTEGRITY OF RNA SAMPLES 
RNA samples are susceptible to degradation by RNases, a family of enzymes present in 
virtually all living cells. These enzymes can degrade RNA molecules through both 
endonucleolytic and exonucleolytic activity, and are fairly resistant to most denaturants. 
Therefore, although the development of better RNA-isolation procedures has reduced the risk 
of RNase contamination, cautious handling of RNA samples is important. Besides RNase-
mediated degradation, DNA and protein contamination resulting from incomplete RNA 
purification are the most prominent reasons for impairment of RNA analysis. The laborious 
and expensive nature of RNA analyses underlines the necessity of preliminary quality 
assessment. Gel electrophoresis and optical densitometry are convenient and common 
methods used in this respect. Positive results in both of these tests indicate good sample 
quality. 
2.6.1 Gel electrophoresis 
Electrophoresis on an agarose gel is the single best diagnostic available for validating the 
quality of purified RNA. Denatured RNA produces a characteristic banding profile upon gel 
electrophoresis, good quality samples presenting with a minimum of smear above, between, 
and below the bands of the abundant 28S and 18S ribosomal (r) RNAs. Lack of definition of 
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the 28S and 18S rRNA bands usually implies that the sample has suffered nuclease attack, 
especially if the smearing is confined to the lower portion (i.e., the leading edge) of the gel. 
However, smearing may also result from incomplete denaturation of secondary structures 
prior to electrophoresis or presence of detergents or excess salt in the sample. Further 
investigative steps should be commenced in order to determine the cause of a poor outcome 
of this test, and, if proved necessary, additional measures should be undertaken in the future 
to avoid DNA or protein contamination, or RNase activity. 
Materials 
- Casting tray, 10 x 15 cm (Bio-Rad™, Richmond, USA) 
- Wide Mini-SUB® gel box (Bio-Rad™, Richmond, USA) 
- Model 200/2.0 Power supply (Bio-Rad™, Richmond, USA) 
- Seakem® LE Agarose (FMC® BioProducts, Maine, USA; cat.no: 50004) 
- 37 % (12.3 M) Formaldehyde (Sigma-Aldrich Co., St. Louis, USA; cat.no: F 8775) 
- 10x MOPS (3-morpholinopropanesulfonic acid)-buffer:  
 · 0.2 M MOPS, pH 7.0 (MOPS hemisodium salt: Sigma-A Co., St. Louis, USA; cat.no: M 1254) 
 · 50 mM Sodium acetate (0.3 M solution: Sigma-Aldrich Co., St. Louis, USA; cat.no: S 8388)  
 · 10 mM EDTA, pH 8.0 (powder: Sigma-Aldrich Co., St. Louis, USA; cat.no: E 9884) 
- 10x loading buffer: 
 · 50 % glycerol (Sigma-Aldrich Co., St. Louis, USA; cat.no: G 5516) 
 · 1 mM EDTA, pH 8.0 (powder: Sigma-Aldrich Co., St. Louis, USA; cat.no: E 9884) 
 · 0.25 % bromophenol blue (powder: Sigma-Aldrich Co., St. Louis, USA; cat.no: B 0126) 
- NorthernMax® Formaldehyde Load Dye (Ambion® Inc., Texas, USA; cat.no: 8552) 
- Diethyl pyrocarbonate (Sigma-Aldrich Co., St. Louis, USA; cat.no: D 5758) 
- Ethidium bromide (Sigma-Aldrich Co., St. Louis, USA; cat.no: E 8751) 
- 100 % ethanol (Arcus AS, Norway) 
- Block heater (Stuart Scientific Co., United Kingdom; cat.no: SH1200D) 
- Gibco BRL UV Transilluminator TFX-35M (Life Technologies™, Rockville, USA) 
- Kodak® Image Station 440 CF (Kodak Digital Science™, New York, USA) 
Method 
The casting tray was mounted and levelled. A comb-shaped device designed to form 15 wells 
of 5.5 x 1.5 mm was placed in the tray, traversing it a few centimetres from the edge. A 
denaturing agarose gel was prepared: 1 g Seakem® LE Agarose was added to 95 ml 1 % 
MOPS-buffer in an erlenmeyer (lidded), and allowed to swell at room-temperature for one 
minute. The agarose was then dissolved completely during microwave heating for 3-4 
minutes in the lidded container, which was subsequently placed in a 55-60 °C water bath. 
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Water-loss was compensated with sterile DEPC-treated water (1 µl diethyl pyrocarbonate 
(DEPC) per ml distilled water, stored overnight and autoclaved), followed by re-tempering to 
55 °C. Five ml of formaldehyde, also tempered to 55 °C, was added to the solution, yielding a 
final concentration of approximately 0.6 M. Immediately thereafter, and in a fume-hood to 
prevent circulation of toxic fumes, the solution was poured onto the center of the casting tray 
until completely covering its bottom. Any bubbles were removed with a pipette, and the gel 
was allowed to set. Once solidified, the gel was transferred to the gel box and soaked in 
MOPS-buffer.  
 
Approximately 1 µg of sample RNA was added to a mixture of 2 µl 0.5 µg/ml ethidium 
bromide and 25 µl formaldehyde load dye, and heated for 2 minutes at 95 °C on a heating 
block. This treatment disrupts intra- and inter-molecular RNA structures, thereby preventing 
these from interfering with the electrophoretic migration. After heating, the samples were put 
directly on ice for 2 minutes, before being inserted into the wells of the agarose gel with a 
micro-pipette. The samples were electrophoresed at 95 V for 30 minutes or as long as 
necessary for complete separation of the bands. Due to the negatively charged backbone of 
nucleic acid polymers, the RNA (and any DNA contaminants) migrates in direction of the 
cathode (the positive electrode). After electrophoresis, the gel was inspected visually on a UV 
transilluminator. The result was also recorded with a digital camera (Fig. 2.2). 
 
 
Figure 2.2: Picture showing the 18S and 28S ribosomal 
RNA (rRNA) bands of 5 RNA samples that have been 
separated on an agarose gel to assess the integrity of the 
sample. Note the absence of smear around the rRNA 
bands, which indicates that these samples are of good 
quality. Sample number 2 displays a broad band of 
residual DNA close to the starting well. 
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2.6.2 Spectrophotometry 
This procedure is performed in order to assess the sample RNA concentration, permitting the 
normalization of samples in relation to RNA content. In addition, the results of this test may 
provide some information on sample purity. The concentration and purity of RNA samples 
are determined readily by taking advantage of the ability of nucleic acids to absorb ultraviolet 
light, maximally at 260 nm. Absorbance measurements at this wavelength permit the direct 
calculation of nucleic acid concentration in a sample, according to Beer’s law (53):  
 
[RNA]µg/ml = A260 × dilution × 40.0, where A260  = absorbance at 260 nm 
 Dilution = dilution factor 
 40.0 = average extinction coefficient of RNA 
 
Calculations based solely on A260 afford little information on sample quality and purity, 
however. For this reason, absorbance is also measured at 280 nm, and the A260/A280 ratio is 
calculated. A pure sample of RNA has an A260/A280 ratio of 2.0 ± 0.15. Repeated steps of 
purification may be required if the samples are found to contain impurities such as proteins or 
DNA, which can both affect optical density (OD) readings. 
Materials 
- GeneQuant® densitometer (LKB Biochrom, England) 
- 1 M  Tris (Trizma®)-HCl (Sigma-Aldrich Co., St. Louis, USA; cat.no: T1819) 
Method 
Prior to sample analysis, the densitometer was zeroed to pure Tris-HCl. The RNA samples, 
diluted 1:40 in 10 mM Tris-buffered HCl to provide a stable pH of approximately 7.5, were 
analyzed on the densitometer according to the manufacturer’s instructions. The machine 
automatically estimated the RNA content and the A260/A280 ratio based on readings at 260 and 
280 nm. 
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2.7 ANALYSIS OF GENE EXPRESSION 
Analysis of gene expression was performed using real-time reverse transcriptase polymerase 
chain reaction (RT-PCR). RT-PCR is a two-step procedure designed for the quantification of 
minute amounts of messenger RNA (mRNA). In the first step, the mRNA is converted to 
complementary DNA (cDNA) by the use of an enzyme called reverse transcriptase. The 
second step of RT-PCR entails amplification of the previously formed cDNA by DNA 
polymerases. In real-time RT-PCR, the amount of PCR-product produced during the 
amplification-step is measured continuously, providing more accurate data. This information 
can subsequently be used to calculate the original levels of mRNA in the sample.  
2.7.1 Methodological principles 
Isolated RNA is converted to cDNA through the actions of reverse transcriptases, acting upon 
an array of random primers that anneal to various sequences throughout the RNA molecule. 
The resulting cDNA must be greatly amplified in order to reach detectable amounts. This is 
accomplished with the polymerase chain reaction (PCR) technique. The PCR is typically 
divided into cycles, each cycle consisting of three components; sample denaturation, primer 
annealing, and primer extension. The successive application of these functionally distinct 
components, typically in the form of 30-40 cycles, results in exponential amplification of the 
template molecules. 
 
Sample denaturation, i.e. strand separation, facilitates hybridization of primers to the template 
in the following step of primer annealing. The denaturation is achieved by heating the 
reaction tube to 95 °C for 1-10 minutes (depending on the complexity and nature of the 
target), and includes denaturation of double-stranded template material as well as any 
secondary structures that may have formed within/between primers. Complete denaturation is 
an absolute requirement if any PCR product is to be observed. 
 
Annealing, or hybridization, of the primers to its specific targets is accomplished by lowering 
the temperature of the reaction tube. Depending on the size and composition of the primer, its 
melting point (Tm) typically lies within 42 – 65 °C, above which annealing will not 
commence. Annealing is usually attempted at least 1-2 °C below the lowest calculated Tm of 
the primers involved, for 0.5-2 minutes time. Thermostable DNA polymerases, which are able 
to withstand the temperatures of up to 95 °C that must be applied in order to achieve complete 
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sample denaturation, elongates the annealed primer by sequentially adding nucleotides to its 
3’-end. 
 
When performing quantitative PCR, an internal control, such as glyceraldehyde phosphate 
dehydrogenase (GAPDH) or β-actin, must be established in order to normalize the results to 
variations in template abundance. The transcripts used as internal controls should show 
minimal modulation during the course of the experimental manipulations, and are often 
referred to as housekeeping genes. The internal control may be assessed in the same or 
separate reactions, and utilize the same or different primers as the target. (53) 
2.7.2 Reverse transcription 
Materials 
- Mastercycler gradient thermal cycler (Eppendorf® GmbH, Germany) 
- Optical 96-well reaction plates (AB Inc., Foster city, USA; part no: N801-0560) 
- High Capacity cDNA Archive Kit (AB Inc., Foster city, USA; part no: 4322171) 
 · 10x RT Buffer 
 · 10x RT Random Primers 
 · 25x dNTP Mix, 100 mM 
 · MultiScribeTM reverse transcriptase, 50 U/µl 
- Nuclease-free water (Ambion® Inc., Texas, USA; cat.no: 9937) 
Method 
A mastermix containing random primers, 
deoxynucleotides (dNTPs), reverse 
transcriptase enzyme, and buffer was 
prepared according to Table 2.5. The 
enzyme (Multiscribe™) was added lastly 
due to its vulnerability to shear stress. Approximately 1000 ng RNA, isolated from PBMC 
and dissolved in RNA Storage Solution, was transferred to 0.5 ml eppendorf tubes and diluted 
with nuclease-free water to a total volume of 50 µl. Fifty µl of mastermix was added to each 
sample tube, followed by vortex and pulse centrifugation. The tubes were subsequently 
inserted into the PCR-machine, which was programmed to run for 10 minutes at 25 °C and 
120 minutes at 37 °C, before cooling to 4 °C. cDNA was stored at -20 °C while awaiting 
PCR. 
Ingredients Final concentration 
10x RT-buffer 1x 
25x dNTP 4 mM 
10x Random Primers 1x 
Multiscribe™ 2.5 U/µl 
 
Table 2.5: Mastermix for reverse transcription of RNA. 
RT, reverse transcriptase; dNTP, deoxynucleotides. 
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2.7.3 Primer design 
Designing primers is perhaps the most critical parameter for a successful PCR. The primer 
sequence determines the length of the product, its melting temperature, the yield, and, most 
importantly, the efficiency of the PCR reaction. A poorly designed primer can, for example, 
result in little or no product due to non-specific amplification and/or primer-dimer formation. 
Hence, care should be taken when designing primer and probes for real-time RT-PCR and it is 
strongly recommended to use software specially developed and validated for these purposes. 
 
Primers and probes for real-time RT-PCR were designed using the Primer Expression version 
2.0 software package (Applied Biosystems). This software is designed to identify primers and 
probes that require a minimum of optimization when performing real-time RT-PCR on a 
sequence detection system from Applied Biosystems with default cycling parameters.  
 
First, nucleotide sequences were collected from GenBank via LocusLink 
(http://www.ncbi.nlm.nih.gov/LocusLink/). Exon-intron boundaries were identified for each 
gene using information available via the same website. The nucleotide sequence was 
subsequently imported into Primer Express. Primers and probes were designed according to 
the User’s manual and with the default parameters for ideal primer and amplicon melting 
point (Tm), length and GC content. Briefly, all primers had Tm between 58 and 60 ºC, and the 
probes were designed to have a Tm 8-10 ºC higher than the primers, i.e., 68-70 ºC. One of the 
primers was designed to span an exon-intron boundary to avoid amplification of genomic 
DNA. Moreover, primers were selected to give an amplified fragment (amplicon) between 70 
and 120 base pairs. All primers and probes were further evaluated to avoid oligonucleotides 
with advanced secondary structures and high potential for primer-dimer formation. Finally, a 
BLAST search against GenBank was performed to assure the specificity of the designed real-
time PCR assay, i.e., avoid primers or probes with strong homologies to genes other than the 
intended target. 
 
TaqMan probes were 5’-labeled with the fluorophore FAM (reporter) and 3’-labeled with 
TAMRA for quenching. High-purity oligonucleotides were ordered from Eurogentec. Details 
of the real-time RT-PCR assays used in the study are given in Table 2.6. 
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Table 2.6: Characteristics of the real-time RT-PCR assays used in the study. 
Target Sequence (5’Æ3’) Acc. nr. 
β-actin* (+)-AGGCACCAGGGCGTGAT NM_001101 
 (–)-TCGTCCCAGTTGGTGACGAT  
ENA-78 (+)-AAGTGGTAGCCTCCCTGAAGAAC X78686 
 (–)-CCTTGTTTCCACCGTCCAA  
 FAM-AGGAAATTTGTCTTGATCCAGAAGCCCCT-TAMRA  
GR-α* (+)-TTGGATTCTATGCATGAAGTGGTT X03225 
 (–)-TATCTGATTGGTGATGATTTCAGCTAA  
IL-8 (+)-GCCAACACAGAAATTATTGTAAAGCTT Y00787 
 (–)-CCTCTGCACCCAGTTTTCCTT  
 FAM-CTGATGGAAGAGAGCTCTGTCTGGACCC-TAMRA  
MCP-1 (+)-AAGCTGTGATCTTCAAGACCATTGT S69738 
 (–)-TGGAATCCTGAACCCACTTCTG  
 FAM-CCAAGGAGATCTGTGCTGACCCCAA-TAMRA  
MIP-1α (+)-CTGCATCACTTGCTGCTGACA M23452 
 (–)-CACTGGCTGCTCGTCTCAAAG  
 FAM-TTCAGCTACACCTCCCGGCAGATTCC -TAMRA  
RANTES
*
(+)-CCCAGCAGTCGTCTTTGTCA M21121 
 (–)-TCCCGAACCCATTTCTTCTCT  
* SYBR Green assays; (+), forward primers; (–), reverse primers; Acc. nr., GenBank accession number. ENA, 
epithelial cell-derived neutrophil-activating factor; GR, glucocorticoid receptor; IL, interleukin; MCP, monocyte 
chemoattractant protein; MIP, macrophage inflammatory protein; RANTES, regulated on activation normal T-
cell expressed and secreted. 
2.7.4 Real-time RT-PCR 
In real-time PCR, the PCR products are 
assayed as they accumulate, as opposed to 
performing a fixed number of cycles and 
assessing the amount and variety of products 
at the end of the reaction. The instantaneous 
quantification of product requires techniques 
involving fluorescent labelling reagents, of 
which there are currently four competing 
techniques available that detect amplified 
product with about the same sensitivity: 1) 
The molecular beacons; 2) DNA-binding 
dyes (SYBR Green); 3) hybridization probes; 
4) hydrolysis probes (Taqman). We have 
used both the SYBR Green and the Taqman 
chemistries in our analyses. 
Fig. 2.3: Melting curve obtained for a SYBR 
Green assay. The one clear-cut top indicates that 
the amplification has been performed with high 
target specificity. 
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The SYBR Green method involves 
detection of the binding of a 
fluorescent dye (SYBR Green) to 
DNA. The unbound dye exhibits 
little fluorescence, but during 
elongation increasing amounts of 
dye binds to the new-formed double-
stranded DNA. When monitored in 
real-time, this results in an increase 
in the fluorescence signal that can be 
observed during the polymerisation 
step and that falls off when the DNA 
is denatured. Consequently, 
fluorescence measurements at the 
end of the elongation step of every 
PCR cycle are performed to monitor 
the increasing amount of amplified 
DNA. This method obviates the need 
for target-specific fluorescent 
probes, but its specificity is 
determined entirely by its primers (in contrast to the Taqman assay, where specificity is 
increased by the use of sequence-specific probes). Hence, the accumulation of unspecific 
double-stranded DNA, such as primer-dimers, is also measured. In order to assure the 
specificity when performing SYBR Green-assays, fluorescence can be plotted as a function of 
temperature, thereby generating a melting curve of the amplicon. As the Tm of the amplicon 
depends markedly on its nucleotide composition, it is possible to identify the signal obtained 
from the correct product (Fig. 2.3). 
 
While SYBR Green is a fluorescent intercalator dye, the Taqman assay utilises the 5’-
nuclease activity of the Taq DNA polymerase to hydrolyse a hybridisation probe bound to its 
target amplicon (Fig. 2.4). In the Taqman assay, an oligonucleotide probe hybridizes 
specifically to the target amplicon during the annealing/extension phase of the PCR. The 
probe contains a fluorescent reporter dye at its 5’ end, the emission spectrum of which is 
Figure 2.4: Presentation of the mechanisms involved in 
Taqman real-time PCR. Adapted from Farrell, 1998 (53). 
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quenched by a second fluorescent dye at its 3’ end. As the 5’-exonuclease activity of Taq 
polymerase is double-strand-specific, unbound probe remains intact and no reporter 
fluorescence is detected. Conversely, if the correct target DNA is present in the reaction, the 
probe hybridizes to it after the denaturation step, and remains hybridised until cleaved by the 
DNA polymerase during primer elongation. This separates the reporter and quencher dyes and 
releases quenching of reporter fluorescence emission. As the polymerase will cleave the probe 
only when it is hybridized to its complementary strand, the temperature conditions of the 
polymerisation phase of the PCR must be adjusted to ensure probe binding. Most probes have 
a Tm of around 70 °C; therefore, the Taqman system uses a combined annealing and 
polymerisation step at 60-62 °C. 
The more templates present at the beginning of the reaction, the fewer number of cycles it 
takes to reach a point in which the fluorescent signal is first recorded as statistically 
significant above background. This point is defined as the Ct (threshold cycle). The reporter 
signal is normalized to the fluorescence of an internal dye (i.e., ROX) to adjust for changes in 
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Figur 2.5: Fluorescence detection during real-time PCR. The curves illustrate amplification of four 1:1 dilutions 
of pooled material, constituting a standard curve. For each dilution, the threshold cycle (Ct) increases with one 
unit. 
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concentration or volume, and a Ct value is reported for each sample. This value can be 
translated into a quantitative result by constructing a standard curve (Fig. 2.5). (53, 54) 
 
In the present study, sample mRNA levels were quantified in reference to a standard curve 
constructed from pooled material containing equal amounts of each of the samples included in 
the analysis. A series of 1:1 dilutions of the pooled material is analyzed along with the 
samples, producing a standard curve to which the other samples are compared by means of 
their respective Ct-value. Hence, the results reflect the relative abundance of target mRNA in 
the study population. 
 
In addition to normalizing for the amount of total RNA, sample-to-sample variation was 
normalized by comparison to an internal standard mRNA. The ideal internal standard should 
be expressed at a constant level among different tissues of an organism, at all stages of 
development, and should be unaffected by the experimental treatment. Moreover, the 
endogenous control should also be expressed at roughly the same level as the RNA under 
study. The mRNAs commonly used as so-called housekeeping genes entail glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH), β-actin and ribosomal RNAs (rRNA). 
 
Materials 
- 2x qPCR™ SYBR® Green m.mix (Eurogentec Ltd., Belgium; cat.no: RT-QP2X-03) 
 · Includes SYBR® Green I dye, 1/2000 
- 2x qPCR™ TaqMan® m.mix (Eurogentec Ltd., Belgium; cat.no: RT-SN2X-03) 
- TaqMan® probes, 5 µM (see Table 2.6; Eurogentec Ltd., Belgium) 
- Primers, 30 µM (see Table 2.6; Eurogentec Ltd., Belgium) 
- Nuclease-free water (Ambion® Inc., Texas, USA; cat.no: 9937) 
- Optical 96-well reaction plates  (AB Inc., Foster city, USA; part no: N801-0560) 
- ABI PRISM 7000 Sequence Detection System (AB Inc., Foster city, USA) 
 
Table 2.7: Mastermix for real-time RT-PCR. 
 
 
 
 
 
 
 
Ingredients Final concentration 
Mastermix 1x 
Forward primer 300 nM 
Reverse primer 300 nM 
Taqman probe (when used) 200 nM  
SYBR Green dye (when used) 1/67,000 
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Method 
A mastermix containing forward and reverse primers, a fluorescent labelling reagent  (either 
SYBR Green dye or TaqMan probe), assay-specific mastermix (depending on the labelling 
reagent), and nuclease-free water was prepared (see Table 2.6). Ten µl cDNA of each sample 
was diluted to 100 µl with nuclease-free water, mixed on vortex, and spun down (quick-spin). 
Standards were prepared from a pool consisting of 10 µl cDNA from all samples. Two 
parallels of each sample were transferred to an optical 96-well reaction plate and mixed with 
mastermix; 3.8 µl diluted cDNA and 21.2 µl mastermix, respectively. The plate was covered 
with an adhesive strip of optical quality and the contents spun down (quick-spin). The ABI 
PRISM 7000 thermal cycler was programmed to run 2 minutes at 50 °C and 10 minutes at 95 
°C (in order to activate the polymerase), followed by 40 cycles of 15 seconds at 95 °C and 1 
minute at 60 °C. A melting curve was obtained in all SYBR Green runs. After the run was 
completed, the threshold line was adjusted to an optimal position in the area of exponential 
amplification (see Fig. 2.5), whereupon the samples were assigned a value by comparison 
with the standard curve. This value was normalized to the corresponding value for β-actin, 
and used to assess the relative chemokine expression in the present sample, compared to the 
other samples.  
2.8 ENZYME-LINKED IMMUNOSORBENT ASSAY 
Enzyme-linked immunosorbent assays (ELISAs) are frequently utilized in the quantification 
of proteins in biological samples. This method provides semi-quantitative data on sample 
protein content, and, depending on the sensitivity and specificity of the antibodies employed, 
affords a lower detection limit in the order of pg/ml.  
 
Monoclonal capture antibodies (cAb) fixed to the bottom of the 
wells of a microtiter plate captures specifically their cognate 
antigen (Ag) when incubated with sample (Fig. 2.6). A 
secondary antibody, the detection antibody, binds the resulting 
protein-cAb complex. In order to enhance the assay sensitivity, 
the detection antibody is linked covalently to a biotin residue, 
which binds streptavidin with high affinity. A peroxidase 
enzyme (horse-radish peroxidase; HRP) covalently bound to 
streptavidin consequently associates 1:1 with antibody-captured 
antigens and will, upon incubation with substrate solution, 
Ag 
HRP 
Streptavidin 
Biotin 
Substrate 
Detection 
antibody 
Capture 
antibody 
Figure 2.6: Model of sandwich 
ELISA. HRP, horse-radish 
peroxidase; Ag, antigen.  
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produce quantities of coloured product that are directly proportional to the amount of 
complexed protein available. Optical densitometry is employed in the quantification of 
product, and semi-quantitative results are obtained by comparison with a standard curve 
generated with known amounts of antigen. 
Materials 
- 96-well microtiter plates (Costar®, New York, USA; cat.no: 9018) 
- ELISA kits and reagents from R&D Systems Inc., Minneapolis, USA as depicted in 
Table 2.7 (catalogue numbers in parentheses) 
- Tecan® Washer 430 (Organon Teknika Inc., Austria) 
- Multiscan RL spectrophotometer (Labsystems Inc., Finland) 
Table 2.7: Enzyme-linked immunosorbent assays used in the present study. RANTES, regulated on activation 
normal T-cell expressed and secreted; ENA, epithelial cell-derived neutrophil-activating factor; MIP, 
macrophage inflammatory protein; MCP, monocyte chemoattractant protein; IL, interleukin; PBS, phosphate-
buffered saline; BSA, bovine serum albumine; TBS, Tris-buffered saline. 
Chemokine Reagents Diluent Working concentration Chemokine Reagents Diluent 
Working 
concentration 
cAb PBS 1 µg/ml cAb PBS 1 µg/ml 
dAb 10 ng/ml dAb 100 ng/ml 
Std 1000 pg/ml Std 1000 pg/ml 
Spl 1/50
a, 1/20b, 
1/50-1/100c 
Spl 1/2
a, 1/10b, 
1/100c 
RANTES 
- 
CCL5 
(DY278) 
S-HRP 
1 % BSA in 
PBS 
1/200 
MCP-1 
- 
CCL2 
(DY279) 
S-HRP 
1 % BSA in 
PBS 
1/200 
cAb PBS 2 µg/ml cAb PBS 4 µg/ml 
dAb 100 ng/ml dAb 20 ng/ml 
Std 1000 pg/ml Std 2000 pg/ml 
Spl 1/2
a, 1/5-1/50b, 
1/20-1/100c 
Spl 1/2
a, 1/100b, 
1/100c 
ENA-78 
- 
CXCL5 
(DY254) 
S-HRP 
1 % BSA in 
PBS 
1/200 
IL-8 
- 
CXCL8 
(DY208) 
S-HRP 
0.1 % BSA, 
0.05 % 
Tween 20 
in TBS 
1/200 
cAb PBS 0,4 µg/ml 
dAb 200 ng/ml 
Std 500 pg/ml 
Spl 1/2
a, 1/25b, 
1/300c 
MIP-1α 
- 
CCL3 
(DY270) 
S-HRP 
1 % BSA in 
PBS 
1/200 
cAb = Capture antibody 
dAb = Detection antibody 
Std = Standard (high) 
Spl = Sample 
S-HRP = Streptavidin horse-radish peroxidase 
a Sample dilutions utilized when assessing serum samples 
b Sample dilutions utilized when assessing cell supernatant samples stimulated or not with MP 
c Sample dilutions utilized when assessing cell supernatant samples stimulated with SEB alone or SEB and MP together 
 
Method 
The levels of the CC-chemokines MCP-1, MIP-1α, and RANTES and the CXC-chemokines 
IL-8 and ENA-78 in cell-culture supernatants and serum were analyzed by ELISA according 
to the manufacturer’s instructions. Reagents were diluted as depicted in Table 2.7. All 
incubations were made at room temperature, during which the plates were covered with an 
adhesive strip. 
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A 96-well microtiter plate was coated by incubation overnight with capture antibody (cAb). 
The wells were subsequently washed three times with 400 µl 0.05 % Tween 20 in phosphate 
buffered saline (PBS), using an automated washer. Following washing, the plate was blocked 
(to prevent unspecific binding of dAb) by adding 300 µl of 1 % BSA, 5 % sucrose and 0.05 % 
NaN3 in PBS to each well, whereupon the plate was incubated for a minimum of 1 hour. After 
a second washing, 100 µl of sample or standard was added per well, and the plate was 
incubated for 2 hours. The washing-procedure was repeated, and 100 µl of detection antibody 
(dAb) was added to each well, followed by 2 more hours of incubation. Subsequent to another 
round of washing, 100 µl of a 1:1 mixture of hydrogen peroxide and tetramethylbenzidine 
was added to each well. The plate was incubated for 20 minutes, while protecting the 
photosensitive reactions from direct light exposure. Finally, 50 µl of 2 M H2SO4 was added to 
each well to stop the reaction. The optical density of each well was determined immediately 
thereafter, using a microplate reader set to 450 nm, with wavelength correction at 540 nm. 
2.9 STATISTICAL ANALYSIS 
As our data could not be expected to be normally distributed, all analyses were performed 
with nonparametric tests. Three different statistical methods were employed in evaluating the 
results: 1) Mann-Whitney test; 2) Wilcoxon signed rank test; 3) Spearman correlation. The 
Mann-Whitney test, also called the rank sum test, is a nonparametric t-test that compares two 
unpaired groups. The Wilcoxon matched pairs test is a test to compare two paired groups. It is 
also called the Wilcoxon matched pairs signed ranks test. Spearman correlation is a method 
for correlating nonparametric data. 
 
In assessing differences between patient and control groups the Mann-Whitney U-test was 
used. Data are presented as scatter-plots, with the median indicated by a horizontal line. 
Probability values are two-sided and taken as statistically significant at P < 0.05. The 
correlation studies were performed using the nonparametric Spearman correlation method. 
When comparing differences between groups of differently treated PBMC within the same 
individual, the Wilcoxon signed rank test was used. Comparisons between the patient and 
control subpopulations were performed using the Mann-Whitney U-test. Data is given as 
mean ± S.E.M. if not otherwise stated. Probability values are two-sided and taken as 
statistically significant at P < 0.05. 
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3. RESULTS 
3.1 SERUM LEVELS OF CHEMOKINES IN WG PATIENTS  
3.1.1 Chemokine levels differ in WG patients and healthy individuals 
The serum levels of IL-8, MIP-1α, MCP-1, RANTES, and ENA-78 in 14 WG patients and 9 
healthy controls were assessed by ELISA (Fig. 3.1). RANTES and MCP-1 were found to be 
significantly up-regulated in WG-patients, compared to healthy controls. In addition, there 
was a strong tendency towards increased levels of IL-8 in the patient population (P = 0.057). 
There were no significant differences in the serum levels of MIP-1α and ENA-78. 
WG Controls
0
2
4
6
8
10
25
30 0.0587A
IL
-8
 [p
g/
m
l]
WG Controls
0
25
50
75
100 P < 0.01D
R
A
N
TE
S 
[n
g/
m
l]
WG Controls
0
100
200
300B
M
IP
-1
α  
[p
g/
m
l]
WG Controls
0
1000
2000
3000E
EN
A
-7
8 
[p
g/
m
l]
WG Controls
0
25
50
75
100 P < 0.01C
M
C
P-
1 
[p
g/
m
l]
Figure 3.1: Scatter-plot showing serumlevels of
interleukin (IL)-8 (A), macrophage inflammatory 
protein (MIP)-1α (B), monocyte chemoattractant 
protein (MCP)-1 (C), regulated on activation 
normal T-cell expressed and secreted (RANTES)
(D), and epithelial cell-derived neutrophil-
activating factor (ENA)-78 (E) in WG patients (n
=14) and healthy controls (n = 9). The results were 
obtained using enzyme-linked immunosorbent 
assays (ELISAs).  
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3.1.2 Chemokines in WG – Relation to clinical markers of inflammation 
We wanted to investigate whether the enhanced serum chemokine levels could reflect 
systemic inflammation. Hence, we performed correlation analyses to determine the 
relationship between serum chemokine levels and clinical inflammation-markers, i.e., CRP 
and ESR. Both ESR and the levels of CRP are widely used clinically in assessing the patient’s 
immune status, and are also employed in the evaluation of disease activity in WG. Correlation 
factors and P-values were calculated using GraphPad Prism® software, and the results are 
listed in Table 3.1. 
 
 
Only RANTES is displaying significant correlations with any of the two inflammation-
markers investigated, being inversely correlated with serum CRP levels (P = 0.0411). 
Considering the small number of subjects investigated, however, some of the other results 
may also prove to be of interest: Both MIP-1α and MCP-1 tend towards being related to the 
levels of CRP in an inverse manner (P = 0.1456 and P = 0.1131), which might have proven 
significant in a larger population. Furthermore, IL-8 tends, although weakly, to be positively 
correlated with ESR (P = 0.1252). 
 
 
 
 
 
 
Table 3.1: Data from correlation-studies 
conducted on the findings in serum of 14 WG 
patients. Serum chemokine levels are compared 
to erythrocyte sedimentation rate (ESR) and the 
levels of C-reactive protein (CRP). Correlation 
factors and P-values were calculated using 
GraphPad Prism® software. RANTES, regulated 
on activation normal T-cell expressed and 
secreted; MIP, macrophage inflammatory 
protein; IL, interleukin; MCP, monocyte 
chemoattractant protein; ENA, epithelial cell-
derived neutrophil-activating factor. 
ESR Chemokine 
Spearman r P-value 
RANTES -0.29 0.3855 
MIP-1α -0.33 0.3176 
IL-8 0.49 0.1252 
MCP-1 -0.17 0.6115 
ENA-78 0.24 0.4669 
 
CRP Chemokine 
Spearman r P-value 
RANTES -0.59 0.0411 
MIP-1α -0.44 0.1456 
IL-8 0.12 0.6992 
MCP-1 -0.48 0.1131 
ENA-78 0.017 0.9561 
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3.1.3 Serum chemokine levels in active and remissive disease 
As mentioned above, the disease activities of the WG patients included in the present study 
were classified as either “active” or “in remission”. To further explore the role of chemokines 
in WG, we went on to investigate whether chemokine levels differed between patients 
classified as “active” or “in remission (Fig. 3.2). No statistically significant differences were 
revealed, although tendencies were evident for RANTES and ENA-78, with up-regulated 
levels of ENA-78 in active patients (P = 0.1419) and up-regulation of RANTES in the WG 
patients that were in remission (P = 0.1812).  
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Figure 3.2: Scatter-plot showing serum levels of interleukin (IL)-8 (A), macrophage 
inflammatory protein (MIP)-1α (B), monocyte chemoattractant protein (MCP)-1 (C), regulated 
on activation normal T-cell expressed and secreted (RANTES) (D), and epithelial cell-derived 
neutrophil-activating factor (ENA)-78 (E) in WG patients with active (n = 8) or remissive (n = 6) 
disease. The results were obtained using enzyme-linked immunosorbent assays (ELISAs).  
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3.2 IN VITRO MANIPULATION OF PBMC 
Having demonstrated significantly elevated serum levels of several chemokines in patients 
with WG, we wanted to investigate the effects of MP on basal and SEB-stimulated chemokine 
expression in PBMC from patients with WG and healthy controls. In order to establish the 
appropriate conditions to be used in the main study, preliminary experiments were conducted.  
3.2.1 Pilot study I 
The first pilot study was performed to examine the effects of stimulation of PBMC with 
different doses of SEB and MP and the outcome of adding the substances at different time-
points (chapter 2.4.3). This experiment revealed that SEB markedly up-regulated the release 
of MCP-1, whereas MP significantly reduced it (Fig. 3.3).  Furthermore, the effects of SEB 
were seemingly independent of the concentrations utilized, indicating that 0.01ng/ml SEB is 
sufficient to reach maximum stimulation of PBMC. On the other hand, MP counteracted SEB 
in a dose-dependent manner, 10-6 M producing the greatest effect. In light of the results from 
pilot study I, 1 ng/ml SEB and 10-6 M MP were used in the following experiments. 
3.2.2 Pilot study II 
With this second pilot study, we were aiming to find the most appropriate timing of cell 
harvesting (chapter 2.4.4). In order to assess the temporal variations in mRNA levels 
following stimulation, PBMC that had been cultured with medium containing SEB and/or MP 
were harvested at four intervals (6, 8, 12, and 24 hours, respectively). When looking into the 
gene expression of biologic mediators, one has to realize that the levels of mRNA only 
represent an instantaneous image of cellular conditions. Therefore, it is expected that the 
levels of mRNA will vary considerably during a period of 24 hours stimulation. The kinetics 
of different chemokines expectedly varies a lot, and, consequently, this second preliminary 
study focused on the effects of SEB and/or MP on two different chemokines, MCP-1 and 
MIP-1α, and also a chemokine receptor, CCR5, one of the receptors for MIP-1α. Messenger 
RNA levels were analyzed using real-time RT-PCR and normalized to the concurrent levels 
of β-actin mRNA. 
 
Stimulation with SEB greatly up-regulated the levels of MIP-1α mRNA at all the selected 
intervals, but the induction, and also, apparently, the MP counteraction, were greatest at 12 
hours (Fig. 3.4A). The levels in PBMC treated with MP alone, and in non-stimulated cells, 
were markedly lower than for the SEB-treated cells. The effects on MCP-1 were equally 
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profound as those on MIP-1α (Fig. 3.4B). However, the response maximum occurred much 
earlier than for the previous. Already at 6 hours, the effects of both SEB and MP were 
maximal. The levels of expression in non-induced cells were low, but the levels in MP-treated 
cells were even lower, although seeming to approach the levels of the non-stimulated cells 
during prolonged incubation. The time-dependent effects on the chemokine receptor, CCR5, 
were less clear-cut than for its ligands (Fig. 3.4C). 
 
In conclusion, it is difficult to predict at which time the levels of all chemokines are maximal, 
and, consequently, we decided to stimulate the PBMC for both 6 and 24 hours in the 
subsequent studies. Hopefully, this would provide more precise results in our evaluation of 
effects of MP and SEB on the production of chemokines in PBMC. 
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Figure 3.3: Bar graphs showing the 
secretion of monocyte chemoattractant 
protein (MCP)-1 by peripheral blood 
mononuclear cells (PBMC) from 2 patients 
with Wegener’s granulomatosis (WG) and 
one healthy control in response to 
treatment with staphylococcal enterotoxin 
B (SEB) or methylprednisolone (MP) or 
both at three different concentrations (SEB: 
0.01 ng/ml, 1 ng/ml, and 100 ng/ml; MP: 
10-8 M, 10-7 M, and 10-6 M) for 24 hours, 
adding SEB either before (A), concurrently 
(B) or after (C) addition of MP. MCP-1 
secretion was assessed using an enzyme-
linked immunosorbant assay (ELISA). 
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Figure 3.4: Bar graphs showing the effects 
of stimulation of peripheral blood 
mononuclear cells (PBMC) from a healthy 
subject with 1 ng/ml staphylococcal 
enterotoxin B (SEB) and/or 10-6 M 
methylprednisolone (MP) on the gene 
expression of macrophage inflammatory 
protein (MIP)-1α (A), monocyte 
chemoattractant protein (MCP)-1 (B), and 
CC-chemokine receptor 5 (CCR5) (C). 
PBMC were stimulated for 6, 8, 12, or 24 
hours, respectively. Gene expression was 
quantified using real-time reverse 
transcriptase polymerase chain reaction 
(RT-PCR) and related to the gene 
expression of β-actin. 
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3.3 MODULATION OF THE PRODUCTION AND SECRETION 
OF CHEMOKINES IN PBMC 
Following the preliminary studies referred above, we concluded that the most favourable 
conditions for stimulation of PBMC in the subsequent analysis of chemokine production and 
secretion would be 1 ng/ml SEB, 10-6 M MP, and incubation for both 6 and 24 hours.  
3.3.1 Effects on protein secretion from PBMC 
Subsequent to incubation for 24 hours with or without 1 ng/ml SEB and/or 10-6 M MP, the 
secretion of IL-8, MIP-1α, MCP-1, RANTES, and ENA-78 was analyzed with ELISA. The 
secretion of IL-8 was reduced to a third following treatment with MP (P < 0.005), whereas the 
SEB-induced up-regulation of chemokine secretion was nearly halved in response to MP in 
both WG patients and healthy controls (P < 0.005; Fig. 3.5). MIP-1α displayed a similar 
pattern (Fig. 3.6), with highly significant modulation of chemokine levels in response to both 
MP and SEB, although not displaying down-regulation in response to MP treatment in the 
patient population. 
 
While the effect of MP on release of MCP-1 paralleled that observed for IL-8 and MIP-1α in 
healthy controls (Fig. 3.7), it did not apply for WG patients, as it failed to produce significant 
down-regulation of both unstimulated and SEB-conditioned PBMC. There was, however, a 
tendency towards a reduction in secreted levels following treatment of MP alone (P = 
0.0742). On the other hand, MP had profound effects on the secretion of RANTES (Fig. 3.8) 
from PBMC from both WG patients and healthy controls, although the effects on the 
spontaneous release of RANTES in PBMC from WG patients were not significant. 
Interestingly, PBMC from healthy controls produced significantly lower levels of RANTES 
than PBMC from WG patients when treated with MP alone (P < 0.05), although the 
spontaneous release of RANTES was the same. 
 
The effects of MP/SEB on secretion of the CXC-chemokine ENA-78 (Fig. 3.9) markedly 
differed from the other chemokines, including the CXC-chemokine IL-8. No significant 
effects were evident in the patient population, neither upon MP- nor SEB-stimulation, 
although there was a tendency towards down-regulation of chemokine secretion following 
MP-treatment of unstimulated PBMC (P = 0.0977). In the control population treatment with 
MP alone produced a highly significant down-regulation (P < 0.005), but no effect was seen 
on SEB-conditioned PBMC. 
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Figure 3.5: Bar graph showing the secretion of interleukin (IL)-8 from cultured peripheral blood mononuclear 
cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9) in response to stimulation with 1 ng/ml 
staphylococcal enterotoxin B (SEB) or 10-6 M methylprednisolone (MP) or both for 24 hours. The results were 
obtained using enzyme-linked immunosorbent assay (ELISA). Values are presented as mean ± S.E.M. ** P < 
0.005 when compared to unstimulated levels; †† P < 0.005 when compared to the SEB-induced levels. 
 
Figure 3.6: Bar graph showing the secretion of macrophage inflammatory protein (MIP)-1α from cultured 
peripheral blood mononuclear cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9) in response 
to stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M methylprednisolone (MP) or both for 
24 hours. The results were obtained using enzyme-linked immunosorbent assay (ELISA). Values are presented 
as mean ± S.E.M. ** P < 0.005 when compared to unstimulated levels; †† P < 0.005 when compared to the 
SEB-induced levels. 
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Figure 3.7: Bar graph showing the secretion of monocyte chemoattractant protein (MCP)-1 from cultured 
peripheral blood mononuclear cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9)  in response 
to stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M methylprednisolone (MP) or both for 
24 hours. The results were obtained using enzyme-linked immunosorbent assay (ELISA). Values are presented 
as mean ± S.E.M. ** P < 0.005 when compared to unstimulated levels; †† P < 0.005 when compared to the 
SEB-induced levels. 
 
Figure 3.8: Bar graph showing the secretion of regulated on activation normal T-cell expressed and secreted 
(RANTES) from cultured peripheral blood mononuclear cells (PBMC) from WG patients (n = 9) and healthy 
controls (n = 9) in response to stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M 
methylprednisolone (MP) or both for 24 hours. The results were obtained using enzyme-linked immunosorbent 
assay (ELISA). Values are presented as mean ± S.E.M. ** P < 0.005 when compared to unstimulated levels; †† 
P < 0.005 when compared to the SEB-induced levels. 
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Figure 3.9: Bar graph showing the secretion of epithelial cell-derived neutrophil-activating factor (ENA)-78 
from cultured peripheral blood mononuclear cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9) 
in response to stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M  methylprednisolone (MP) 
or both for 24 hours. The results were obtained using enzyme-linked immunosorbent assay (ELISA). Values are 
presented as mean ± S.E.M. ** P < 0.005 when compared to unstimulated levels. 
3.3.2 Effects on gene transcription of PBMC 
Following 6 hours of stimulation with MP in the presence or absence of SEB, the effects on 
gene transcription in PBMC from both patients and healthy controls were assessed by real-
time RT-PCR. It turned out that the expression of several of the chemokines studied was 
profoundly modulated by the treatment. The expression of IL-8, for instance, was 
significantly reduced upon MP-treatment in both patients and controls (P < 0.05 and 0.005, 
respectively) (Fig. 3.10). In spite of the weighty effect of MP on secreted levels of the 
chemokine (Fig. 3.5), however, MP was unable to neutralize the potent up-regulation of IL-8 
gene expression following stimulation with SEB. A similar pattern was observed for the 
expression of MIP-1α and MCP-1, differing only in respect to the effects of MP alone, which 
failed to produce significant down-regulation of gene expression in the patient population. 
 
Interestingly, the levels of RANTES mRNA were only modestly influenced by stimulation 
with SEB or MP, contrasting sharply with our findings on the protein level. Whereas the 
secretion of RANTES was vigorously up-regulated following SEB-treatment, this treatment 
failed to induce a response on gene transcription in the patient population, and, furthermore, 
resulted in down-regulation in the control population (P < 0.05). The same perplexing picture 
was evident for ENA-78; no discernible effect of SEB was monitored. However, MP showed 
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significant effect on the expression of ENA-78 in both WG patients and healthy controls. 
Thus, for several of the chemokines (i.e., IL-8, MIP-1α, and MCP-1), the down-regulatory 
effect of MP on the SEB-stimulated chemokine response was not accompanied by a 
corresponding decrease in mRNA levels, suggesting post-transcriptional modulation of MP. 
 
 
 
Figure 3.10: Bar graph showing the gene expression of interleukin (IL)-8 in cultured peripheral blood 
mononuclear cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9) in response to stimulation 
with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M methylprednisolone (MP) or both for 6 hours. The 
results were obtained using real-time reverse transcriptase – polymerase chain reaction (RT-PCR). Values are 
presented as mean ± S.E.M. * P < 0.05; ** P < 0.005 when compared to unstimulated levels. 
Unstim MP SEB SEB+MP Unstim MP SEB SEB+MP
0
25
50
75
100
125
150
WG Controls
*
**
**
IL
-8
: β-
ac
tin
 m
R
NA
**
Results 
49 
Figure 3.11: Bar graph showing the gene expression of macrophage inflammatory protein (MIP)-1α in cultured 
peripheral blood mononuclear cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9) in response 
to stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M methylprednisolone (MP) or both for 6 
hours. The results were obtained using real-time reverse transcriptase – polymerase chain reaction (RT-PCR). 
Values are presented as mean ± S.E.M. * P < 0.05; ** P < 0.005 when compared to unstimulated levels. 
 
 
Figure 3.12: Bar graph showing the gene expression of monocyte chemoattractant protein (MCP)-1 in cultured 
peripheral blood mononuclear cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9) in response 
to stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M methylprednisolone (MP) or both for 6 
hours. The results were obtained using real-time reverse transcriptase – polymerase chain reaction (RT-PCR). 
Values are presented as mean ± S.E.M. * P < 0.05; ** P < 0.005 when compared to unstimulated levels. 
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Figure 3.13: Bar graph showing the gene expression of regulated on activation normal T-cell expressed and 
secreted (RANTES) in cultured peripheral blood mononuclear cells (PBMC) from WG patients (n = 9) and 
healthy controls (n = 9) in response to stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M 
methylprednisolone (MP) or both for 6 hours. The results were obtained using real-time reverse transcriptase – 
polymerase chain reaction (RT-PCR). Values are presented as mean ± S.E.M. * P < 0.05; ** P < 0.005 when 
compared to unstimulated levels; † P < 0.05 when compared to the SEB-induced levels. 
 
 
Figure 3.14: Bar graph showing the gene expression of epithelial cell-derived neutrophil-activating factor 
(ENA)-78 in cultured peripheral blood mononuclear cells (PBMC) from WG patients (n = 9) and healthy 
controls (n = 9) in response to stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M 
methylprednisolone (MP) or both for 6 hours. The results were obtained using real-time reverse transcriptase – 
polymerase chain reaction (RT-PCR). Values are presented as mean ± S.E.M. * P < 0.05; ** P < 0.005 when 
compared to unstimulated levels. 
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3.4 INFLUENCE OF EXPERIMENTAL TREATMENT ON THE 
EXPRESSION OF GLUCOCORTICOID RECEPTOR MRNA  
The expression of glucocorticoid receptor (GR)-α in PBMC was not significantly affected by 
stimulation with MP. However, SEB produced significant up-regulation of the GR-α mRNA 
levels. There were no significant differences between the patient and control populations 
regarding the level of gene expression of GR-α, although a strong tendency towards elevated 
levels in controls following treatment with SEB+MP was evident (P = 0.0625). 
 
Figure 3.15: Bar graph showing the gene expression of glucocorticoid receptor (GR)-α in cultured peripheral 
blood mononuclear cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9) in response to 
stimulation with 1 ng/ml staphylococcal enterotoxin B (SEB) or 10-6 M methylprednisolone (MP) or both for 6 
hours. The results were obtained using real-time reverse transcriptase – polymerase chain reaction (RT-PCR). 
Values are presented as mean ± S.E.M. * P < 0.05; ** P < 0.005 when compared to unstimulated levels. 
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4. DISCUSSION 
4.1 SUMMARY OF RESULTS 
In the present study we demonstrate that patients with WG have elevated circulating levels of 
the chemokines RANTES and MCP-1. When classifying the patients according to disease 
activity, i.e., as active or in remission, we found a trend for lower RANTES levels and higher 
ENA-78 levels in patients with active disease compared to patients in remission. 
 
We also examined the effects of MP on the in vitro gene expression and release of 
chemokines in PBMC isolated from WG patients and healthy controls. Notably, MP reduced 
both basal and SEB-stimulated chemokine release in PBMC from healthy controls. However, 
the effects of MP on chemokine secretion from PBMC isolated from WG patients were 
variable, suggesting that these patients may have altered glucocorticoid sensitivity. 
Furthermore, the chemokine mRNA levels in PBMC stimulated with SEB were unaffected of 
MP treatment. 
 
Table 4.1: Summary of the effects of methylprednisolone on the release of chemokines from peripheral blood 
mononuclear cells (PBMC) from WG patients (n = 9) and healthy controls (n = 9) that were concomitantly 
stimulated with or without staphylococcal enterotoxin B (SEB).  
WG Patients Controls Chemokine 
Unstim SEB Unstim SEB 
IL-8 ↓ ↓ ↓ ↓ 
MIP-1α — ↓ ↓ ↓ 
MCP-1 — — ↓ ↓ 
RANTES — ↓ ↓ ↓ 
ENA-78 — — ↓ — 
IL, interleukin; MIP, macrophage inflammatory protein; MCP, monocyte chemoattractant protein; RANTES, 
regulated on activation normal T-cell expressed and secreted; ENA, epithelial cell-derived neutrophil-activating 
factor. Data were obtained using enzyme-linked immunosorbent assays (ELISA). 
4.2 INTERPRETATION OF RESULTS 
4.2.1 Potential pathogenic role for chemokines in WG 
Very few studies have addressed the involvement of chemokines in WG. However, a 
pathogenic role has been attributed to IL-8 in ANCA-associated glomerulonephritis (32). 
Correspondingly, Mayet et al. (1999) showed that endothelial IL-8 synthesis was up-regulated 
following stimulation in vitro with anti-PR3-antibodies (55), whereas Ralston et al. (1997) 
found that ANCAs induced monocytic IL-8 release (30). Monocytes are an integral part of 
granulomas and glomerular crescents in active WG (8), while neutrophils, being one of the 
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main targets of IL-8, are suggested to be major effector cells in the development of 
inflammatory lesions in active WG. PR3-ANCAs have been established as an important 
pathogenic factor in WG, and the levels of perinuclear ANCAs (ANCAs showing a 
perinuclear distribution pattern in indirect immunofluorescence, as opposed to cytoplasmic 
ANCAs, which are widely distributed throughout the cytoplasm) are used as markers of 
disease activity (8). In the present study, IL-8 shows a strong tendency for being up-regulated 
in WG patients, compared to healthy controls, further supporting a pathogenic role for this 
chemokine in WG. 
 
Although not concretely associated with WG, the serum levels of RANTES and MCP-1 have 
been shown to be elevated in relation to other autoimmune disorders, including multiple 
sclerosis (MS), rheumatoid arthritis (RA) (27), and systemic lupus erythematosus (SLE) (56). 
Interestingly, Kaneko et al. (1999) observed a decrease in RANTES with the progression of 
disease activity in patients with SLE (56). In the present study, RANTES was negatively 
correlated with CRP, indicating a similar regulation in WG. Furthermore, there was a 
tendency towards down-regulation of the serum levels of RANTES in active WG patients 
compared to patients in remission, substantiating the assumption that RANTES may indeed 
be involved in WG, although in a little surprising manner, which cannot presently be 
explained. However, caution is needed when interpreting data from plasma/serum analyses as 
they may not necessarily reflect the activity in pathologically involved tissues. The levels of 
RANTES in lung tissues have indeed been found to be elevated in WG patients (57). 
 
It has previously been shown that both cytoplasmic and perinuclear ANCAs induce MCP-1 
release from PBMC in vitro, and that MCP-1 is largely responsible for the ANCA-induced 
chemoattraction of mononuclear leukocytes (58). Our demonstration of elevated serum MCP-
1 levels in WG patients is consistent with these findings, and a possible role in determining 
disease activity is substantiated by the inverse correlation of MCP-1 to CRP. Collectively, 
these data suggest that MCP-1 may be involved in the pathophysiology of WG. 
 
The effects of immunosuppressive therapy may partly result from modulation of cytokine and 
chemokine levels. The present study reveals modulation of chemokine levels following in 
vitro stimulation with MP, a widely used immunosuppressant. Moreover, Lamprecht et al. 
(2002) demonstrated that elevated monocytic IL-12 and TNF-α, but not IL-8, in WG was 
normalized by cyclophosphamide and corticosteroid therapy (59). In addition, intravenous 
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pulse methylprednisolone (PMP) treatment of patients with rheumatoid arthritis was shown 
by Wong et al. (2001) to reduce MCP-1 and MIP-1α expression in the synovial lining layer 
within 24 hours of administration (60). This may be due to either a direct effect on chemokine 
production or an indirect effect on other proinflammatory mediators that regulate chemokine 
expression. TNF-α may be important in this context, influencing the production of several 
chemokines, including IL-8 and MCP-1 (61, 62), and playing an important role in granuloma 
formation and the induction of vasculitis in WG, as demonstrated by several clinical and in 
vitro studies (59, 63). 
 
Chemokine up-regulation may also be localized to certain tissues, therefore not necessarily 
producing elevated levels in systemic circulation. Zhou et al. (2003) demonstrated that 
RANTES, MIP-1α, and MIP-1β, all of which are ligands of the chemokine receptor CCR5, 
were enriched in lung lesions from patients with WG, producing localized accumulation of 
CCR5-positive cells (57). Moreover, Lamprecht et al. (2003) recently found that a larger 
fraction of T lymphocytes in localized WG than in generalized WG displayed CCR5 
production, suggesting that these chemokines are primarily involved in the early phases of 
disease (64). 
 
Immunosuppressive therapy of the WG patients may have influenced both serum and PBMC 
levels of chemokines found in the present study. Moreover, the diminished responses 
experienced in PBMC from WG patients to stimulation with MP may result from down-
regulation of GRs as a consequence of long-term GC treatment. Additional mechanisms, 
including up-regulation of GR-β, may also contribute to this unresponsiveness. Furthermore, 
the diverging responsiveness observed may also result from GR-independent post-
transcriptional and post-translational mechanisms. The individualized therapy of WG patients 
may complicate the comparison of active and remissive patients, and inherent differences in 
chemokine levels between WG patients and healthy individuals may be obscured by drug-
induced effects. 
4.2.2 MP modulates chemokines in vitro 
MP had substantial effect on the secretion of chemokines from PBMC isolated from healthy 
controls. In the patient population, however, a significant effect of MP alone was only seen 
for IL-8, although similar tendencies were evident for both MCP-1 and ENA-78. 
Interestingly, while PBMC from the same pair of patients are consistently opposing the down-
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regulatory effects of MP in MIP-1α, RANTES, and MCP-1 (the CC chemokines), every 
patient, except for one, are resistant to modulation by MP in respect of at least one 
chemokine. This suggests a complexity within the regulation of chemokine secretion that we 
are, presently, unable to grasp. Neither medication nor disease activity could explain these 
manifestations in the present study. Correlation studies were indeed performed to reveal 
possible connections between medication and disease activity and PBMC chemokine 
production. However, relating serum levels of chemokines to oral drug dosage must be 
considered a highly inaccurate method, and was only attempted because these were the only 
data available regarding the patients’ medication. A much more precise approach would be to 
compare serum chemokine levels with levels of MP in serum, a feature that should be 
procured in future studies.  
 
The effects of MP were also manifest on the level of gene expression, although not always in 
consistence with our findings on the protein level. The most remarkable difference between 
the two is the lacking effect of MP on mRNA-levels in SEB-conditioned PBMC, an outcome 
that is apparent in both patients and healthy controls and, moreover, for all chemokines 
assessed in the present study, except RANTES. MP produces significant effects when used 
alone, however, ruling out the possibility that the effects seen on chemokine secretion are 
exlusively produced by non-genomic mechanisms. There are no significant differences 
between the effects seen in the two study populations, indicating that the possible existence of 
treatment-induced GC resistance in WG patients submitted to long-term GC therapy is 
without importance in this setting. On the other hand, the GC unresponsiveness seen in SEB-
conditioned PBMC may result from SEB-induced GC resistance, although further 
investigations are required to establish such a connection. 
 
The gene expression of RANTES does not conform to the pattern seen with the other 
chemokines. While down-regulated by MP, the gene expression of RANTES is also down-
regulated with SEB, compared to unstimulated PBMC. Furthermore, the concomitant 
stimulation with SEB+MP results in a RANTES mRNA expression that is significantly lower 
than the levels experienced in unstimulated cells. A down-regulation of mRNA levels 
following SEB-stimulation is also seen with ENA-78, suggesting that different regulatory 
mechanisms may be involved in the production of RANTES and ENA-78. There may be 
several mechanisms in play, influencing differently the production of divergent chemokines. 
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The effects of superantigens on PBMC are non-controversial, a fact that was confirmed 
further in the present study, as chemokine production was generally up-regulated in response 
to stimulation with SEB. SEB-stimulation also resulted in up-regulation of GR-α. This is 
consistent with the findings in a study of Hauk et al. (2000), which concluded that both GR-α 
and GR-β were significantly up-regulated in response to SEB (100 ng/ml for 48 hours), 
although GR-β somewhat more than GR-α (65). Moreover, they found that microbial 
superantigens (SEB and PHA) induced GC insensitivity in PBMC from healthy volunteers, 
probably resulting from the elevated levels of GR-β, which are believed to inhibit the actions 
of GR-α (47). This does not explain, however, the diminished effect of MP on PBMC from 
WG patients. On the other hand, unresponsiveness to GC treatment may also be induced by 
long-term systemic GC therapy, which is the mainstay of maintenance therapy in WG. There 
are also other mechanisms than up-regulation of GR-β that may contribute to this effect, and it 
is presently unclear to what extent up-regulation of GR-β is involved. 
4.3 METHODOLOGICAL CONSIDERATIONS 
4.3.1 In vitro activation of viable cells 
In vitro studies on viable cells may be confounded by preparative stimulation, either by 
contamination of activating agents, or by inappropriate sample handling. Common 
contaminants include bacteria or bacterial surface products (e.g., endotoxins), which provoke 
a state of alertness in leukocytes, reflected by secretion of inflammatory products and up-
regulation of adhesion molecules. These activities may have profound influence on the 
parameters under investigation, and are therefore sought eliminated. In order to minimize the 
risk of contamination, and thereby the hazard of in vitro activation, all handling of viable cell 
samples was performed aseptically in sterile laminar air flow (LAF) cabinets. Furthermore, all 
reagents were routinely checked for endotoxin content by the Lumulus amoebocyte lysate 
(LAL) test. Moreover, our in vitro experiments were designed in such a way that potential in 
vitro activation would not influence the results. For instance, samples that were to be 
compared in respect of cellular function (i.e., chemokine gene expression or secretion) were 
treated identically up to the point of addition of stimulant.  
4.3.2 Experimental stimulation 
Stegeman et al. demonstrated in 1994 that chronic nasal carriage of Staphylococcus aureus 
could be a risk factor for WG relapse, and concluded that this could be due to activation of 
neutrophils, followed by surface-expression of ANCA-antigens, or that staphylococcal 
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superantigens or other immunogenic surface structures (such as peptidoglycan) could 
stimulate lymphocytes independently of T-cell help (10). Therefore, SEB, possibly 
contributing to the pathophysiology of WG, was chosen above phytohemagglutinin (PHA), 
LPS, and CD3, which could otherwise have been equally competent stimulating agents. 
Recently, however, the same group has concluded that the effects of S. aureus are probably 
mediated by a mechanism other than superantigenic T-cell activation because the T cell 
expansion experienced in WG patients was not associated with the presence of either S. 
aureus or its SAgs (52). However, more plausible mechanisms have not yet emerged. 
 
MP was a natural agent of choice when seeking to elucidate the effects of immunosuppressive 
therapy, as this agent is used for induction of remission in WG patients with active disease. 
4.3.3 Assay evaluation 
The assays employed in this study, including both ELISA and real-time RT-PCR applications, 
are previously well-tested for assessing chemokine levels in the medias presently encountered 
(i.e. serum and cell supernatants, and purified RNA, respectively). The analyses in some 
applications were performed repeatedly, but the reproducibility and accuracy of the methods 
employed were not systematically subdued to further inquiry. 
 
The relatively small size of the study populations included in the present thesis limits the 
possibility of finding statistically significant relationships. On the other hand, variations that 
are found to be significant in smaller populations generally are substantial. Furthermore, 
observations that are not statistically significant in smaller populations may as well be so 
when assessed in a larger material, and are said to be tendencies, representing interesting 
areas for future investigation. 
 
High doses of SEB have been reported to induce apoptosis in T lymphocytes (66). The topical 
report utilized SEB in concentrations of 5 µg/ml, which is much higher than the 
concentrations we have used in our study. However, we have reason to believe that apoptosis 
may be seen already at 100 ng/ml, which is partly the reason why a concentration of only 1 
ng/ml was employed in our study. Although we feel confident that apoptosis has not 
influenced the results of our study, this has not been confirmed experimentally. 
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4.3.4 Longitudinal variations in chemokine levels 
The data obtained in this study are based on measurements taken at a single time point only. 
Therefore, longitudinal (over time) variation in chemokine levels can affect the data obtained, 
possibly also influencing the conclusions drawn on basis of the data. Longitudinal changes in 
the circulating levels of some chemokines (IP-10, Mig, eotaxin, and TARC) and chemokine 
receptors (CXCR3, CCR5, and CCR3) have previously been investigated in healthy 
individuals (67). These results indicated a reliable baseline of in vivo expression of 
chemokines and chemokine receptors among healthy subjects. Furthermore, Kivisakk et al. 
(2003) have resently completed a two-year longitudinal study of the constitutive levels of the 
chemokine receptors CCR2, CCR5, and CXCR3 on CD4-positive T cells in healthy 
volunteers, concluding that major fluctuations in chemokine-receptor levels within healthy 
individuals are probably uncommon (68). In WG patients, on the other hand, the chemokine 
levels may fluctuate considerably, most likely in accordance with disease activity. If the 
chemokines we have investigated are involved in the pathophysiology of WG, the condition 
of the patient at sample collection may affect our results considerably. We have, therefore, 
tried to assess this possibility by comparing serum chemokine levels with CRP and ESR. 
4.3.5 Inter-subject variations in chemokine levels 
The study of Campbell et al. (2001) (67) also assessed inter-individual variations in 
chemokine expression. In our study, this is not of importance except for the assessment of 
serum chemokine levels in WG patients versus healthy controls, as our conclusions for the 
most part are based on differences in chemokine expression in aliquots of the same cell 
population, handled identically up to the point of stimulation with inducing agents. 
Nonetheless, Campbell et al. found a high inter-subject variability in the chemokine levels in 
plasma, indicating that large sample populations would be required to identify significant 
differences between disease and control groups. In contrast, we, in the present study, have 
revealed differences between WG patients and healthy controls in the serum levels of 
RANTES and MCP-1 that are sufficiently large to be assessed even in the relatively small 
population included. 
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4.3.6 Presentation of data 
Some ways of presenting data may preclude important information. Although perspicuous, 
bar charts may mislead the interpretation of the results by omitting individual values. The 
figures presented below (Fig. 4.1) will aid in the interpretation of some of the results from this 
study. 
Figure 4.1: Two ways of presenting the secretion of epithelial cell-derived neutrophil-activating factor (ENA)-
78 (upper panel) and interleukin (IL)-8 (lower panel) from peripheral blood mononuclear cells from 9 patients 
with Wegener’s granulomatosis and 9 healthy controls in response to 24 hours stimulation with staphylococcal 
enterotoxin B (SEB) or methylprednisolone (MP) or both. The results are obtained using enzyme-linked 
immunosorbent assays (ELISA). Values are presented as connected scatter-plots (left) and bar graphs (right). 
 
The figures above may provide a more nuanced picture of the modulation of IL-8 and ENA-
78 experienced in this study. Whereas IL-8 is profoundly and unidirectionally modulated by 
the prevailing conditions, the levels of ENA-78 seemingly remains stable upon stimulation, 
particularly in the patient population. However, this is hardly the case; by closer investigation 
of the data, it is revealed that the reason why MP seemingly has no effect on unstimulated 
PBMC from WG patients is that one single sample deviates from the general trend. Due to the 
small study population, no statistical significance is achieved. This does not mean, however, 
that MP has no effect on the secretion of ENA-78. 
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4.3.7 Drawing conclusions 
The results experienced in this study, obtained by analysis on protein as well as mRNA levels, 
depend on a variety of cellular regulatory mechanisms that will not be completely elucidated 
unless further investigations are performed. Figure 4.2 illustrates the many points at which 
chemokine expression may be modulated within the cells analyzed. 
Figure 4.2: Six steps at which gene expression can be controlled. Step 6, the regulation of protein activity, 
includes reversible activation or inactivation by protein phosphorylation as well as irreversible inactivation by 
proteolytic degradation. The figure is modified after Alberts et al., 2002. (69) 
 
Thus, there are a variety of steps on which MP and SEB can act to produce their effects. The 
observation that the secretion of a certain chemokine is modulated in response to one of these 
agents may consequently result from increased gene expression or translation, including post-
transcriptional and post-translational modulation, as well as up-regulated secretion of the 
chemokine. Furthermore, effects observed on the gene expression of a specific chemokine do 
not always imply increased secretion of the chemokine, due to several instances of post-
transcriptional control.  
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4.4 FUTURE CONCERNS 
The pathophysiology of WG is far from elucidated and should therefore, because of the 
possibly fatal nature of this disease, be intensively investigated in the future. We and others 
have suggested a role of chemokines in WG, reflecting either causal or resultant involvement 
in the pathology of this disease. The next step will be to further elucidate the functions of the 
involved chemokines in situ, as well as investigating other factors that may contribute to both 
chemokine levels and disease activity. Both in vitro and in vivo actions of the GCs must be 
further illuminated. Moreover, if indeed the effects on chemokine production are linked to the 
therapeutic effects of immunosuppression, the development of drugs that more selectively 
interact with chemokines or chemokine receptors should be a goal for the distant future. Such 
drugs are, in fact, in the pipeline for the treatment of HIV-infection (70). 
 
For the near future, on the other hand, further studies of PBMC are warranted, including 
investigation of the effects at other stimulation intervals in order to assess temporal variations 
in the gene expression and secretion of chemokines following treatment with MP. Samples 
are indeed in store that have been stimulated for 24 hours, and will be investigated presently. 
Furthermore, the levels of GR-α and -β will be more closely explored, hopefully leading to a 
better understanding of the mechanisms underlying GC resistance. It proved too laborious to 
include these investigations in the present thesis. 
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5. CONCLUSIONS 
The results of the present study suggest a role for chemokines in WG; RANTES, IL-8, and 
MCP-1 in particular. MIP-1α and ENA-78 may be involved as well, although these were less 
convincingly regulated in the present study. We found elevated levels of RANTES and MCP-
1, and also a strong tendency for up-regulation of IL-8, in serum of WG patients. In addition, 
there were tendencies for differential levels of RANTES and ENA-78 in patients with active 
and remissive disease.  
 
The chemokines may also constitute important targets for therapy – clearly, the current 
immunosuppressive therapy, in our study represented by the glucocorticoid MP, influences 
the production of chemokines in PBMC isolated from healthy individuals in vitro. However, 
there is a diminished response in patients, suggesting that potentially important pathogenic 
mechanisms remain unmodulated by the current treatment strategies. 
 
Presently, the treatment of WG is based on drugs with wide-spread and pleomorphic effects, 
resulting in substantial treatment-associated morbidity. Moreover, the development of therapy 
resistance severely impairs treatment efficacy in a significant proportion of the patients. 
Specific modulation of chemokine levels therefore constitutes a promising foundation for 
future treatment strategies in WG.  
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7. APPENDIX 
 
Table 1: Characteristics of the chemokines. Adapted from Olson and Ley, 2002 (19). 
Systematic 
Name* 
Human 
Common 
Names 
Mouse 
Common 
Names 
Receptors
Bound 
Chemokine
Type Expression 
Proposed Functional 
Expression Sites  
CXCL1 GROα, MGSA MIP-2, KC CXCR2 ELR+ Inducible 
CXCL2 GROβ, MIP-2α KC CXCR2 ELR+ Inducible  
CXCL3 GROγ, MIP-2β KC CXCR2 ELR+ Inducible  
Neutrophilic inflammatory 
sites; atherosclerotic 
lesions 
CXCL4 PF4 PF4  ELR–   
CXCL5 ENA-78 LIX CXCR2 ELR+ Inducible 
CXCL6 GCP-2 CKα-3 CXCR1,2 ELR+ Inducible  
CXCL7 NAP-2  CXCR2 ELR+ Inducible  
Neutrophilic inflammatory 
sites Neutrophilic 
inflammatory sites 
Neutrophilic inflammatory 
sites  
CXCL8 IL-8  CXCR1,2 ELR+ Inducible Neutrophilic 
inflammation; liver, acute 
lung injury; atherosclerotic 
lesions  
CXCL9 Mig Mig CXCR3 ELR– Inducible 
CXCL10 IP-10 IP-10, CRG-2 CXCR3 ELR– Inducible  
Th1 inflammation; CNS, 
intestinal lesions  
CXCL11 I-TAC  CXCR3 ELR– Inducible Th1 inflammation  
CXCL12 SDF-1 SDF-1 CXCR4 ELR– Constitutive Bone marrow; thymus; 
lung; lymphoid organs  
CXCL13 BLC, BCA-1 BLC, BCA-1 CXCR5 ELR– Constitutive Lymphoid follicles  
CXCL14 BRAK, 
bolekine 
  ELR–   
CXCL15  lungkine  ELR–   
CXCL16 CXCL16 CXCL16 CXCR6 ELR–, 
TMD+ 
 Th1 inflammation  
CCL1 I-309 TCA-3 CCR8 4 cysteines Inducible Th2 inflammation  
CCL2 MCP-1, MCAF JE CCR2 4 cysteines Inducible Th1 inflammation; liver, 
CNS, allergic lung injury; 
atherosclerotic lesions  
CCL3 MIP-1α MIP-1α CCR1,5 4 cysteines Inducible 
CCL4 MIP-1β MIP-1β CCR5,8 4 cysteines Inducible  
Th1 inflammation; lung, 
CNS, atherosclerotic 
injury  
CCL5 RANTES RANTES CCR1,3,5 4 cysteines Inducible Th1, Th2 inflammation; 
Lung, CNS, skin injury; 
atherosclerotic lesions  
CCL6  MRP-1  4 cysteines   
CCL7 MCP-3 MARC CCR1,2,3 6 cysteines Inducible 
CCL8 MCP-2 MCP-2 CCR3 4 cysteines Inducible  
Th1, Th2 inflammation; 
CNS, lung injury  
CCL9  MRP-2, MIP-
1γ 
 6 cysteines   
CCL10  CCF-18  4 cysteines   
CCL11 eotaxin eotaxin CCR3 4 cysteines Inducible Th2 inflammation; allergic 
lung, skin disease  
CCL12  MCP-5 CCR2 4 cysteines Inducible 
CCL13 MCP-4  CCR2,3 4 cysteines Inducible  
Th1, Th2 inflammation; 
allergic lung disease  
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CCL14 HCC-1, CKβ-1   CCR1 4 cysteines   
CCL15 HCC-2, Lkn-1, 
MIP-5 
 CCR1,3 6 cysteines   
CCL16 HCC-4, LEC, 
Mtn-1 
LCC-1 CCR1 4 cysteines   
CCL17 TARC TARC CCR4 4 cysteines Inducible Th2 inflammation in skin  
CCL18 DC-CK1, 
PARC 
  4 cysteines Constitutive Lymphoid T cell zones  
CCL19 MIP-3β, ELC, 
CKβ-11 
MIP-3β, ELC CCR7 4 cysteines Constitutive Lymphoid T cell zones  
CCL20 MIP-3 , LARC MIP-3α, 
LARC 
CCR6 4 cysteines Constitutive Intestinal villi; skin  
CCL21 6Ckine, SLC, 
CKβ-9 
SLC, TCA-4 CCR7 6 cysteines Constitutive Lymphoid organs, HEV  
CCL22 MDC, STCP1 abcd-1 CCR4 4 cysteines Both Thymus; allergic lung 
disease; Th2 inflammation 
CCL23 MPIF-1, CKβ-8  CCR1 6 cysteines   
CCL24 MPIF-2, 
eotaxin-2 
 CCR3 4 cysteines Inducible Th2 inflammation  
CCL25 TECK, CKβ-15 TECK, CKβ-
15 
CCR9 4 cysteines Constitutive Small intestine; thymus  
CCL26 eotaxin-3, MIP-
4α 
 CCR3 4 cysteines Inducible Th2 inflammation  
CCL27 CTACK, ILC, 
ESkine 
ALP, skinkine CCR10 4 cysteines Constitutive Skin  
CX3CL1 fractalkine neurotactin CX3CR1 TMD+ both Ubiquitous  
XCL1 lymphotactin, 
ATAC 
lymphotactin XCR1    
* Systematic nomenclature and mouse/human correlation defined by Zlotnik and Yoshie (71). GRO, growth-
related oncogene; MGSA, melanoma growth stimulatory activity; MIP, macrophage inflammatory protein; PF, 
platelet factor; ENA, epithelial cell-derived neutrophil-activating factor; LIX, lipopolysaccharide-induced CXC 
human chemokine; GCP, granulocyte chemotactic protein; CK, chemokine; NAP, neutrophil-activating protein; 
IL, interleukin; Mig, monokine induced by γ-interferon; IP-10, γ-interferon-inducible protein; CRG, chemokine 
responsive to gamma; I-TAC, interferon-inducible T-cell chemoattractant; SDF, stromal cell-derived factor; 
BCA-1, B-cell-activating chemokine; BLC, B-lymphocyte chemoattractant; BRAK, breast and kidney 
expressed chemokine; TCA, T-cell-activation protein; MCP, monocyte chemoattractant protein; MCAF, 
monocyte chemotactic and activating factor; RANTES, regulated on activation normal T-cell expressed and 
secreted; MRP, MIP-related protein; CCF, CC chemokine factor; HCC, hemofiltrate CC chemokine; Lkn, 
leukotactin; LEC, liver expressed chemokine; Mtn, monotactin; LCC, liver-specific CC chemokine; TARC, 
thymus- and activation-related chemokine; DC-CK, dendritic cell chemokine; PARC, pulmonary- and 
activation-regulated chemokine; ELC, Epstein-Barr virus-induced receptor ligand chemokine; LARC, liver- and 
activation-induced chemokine; 6Ckine, 6 cysteine chemokine; SLC, secondary lymphoid tissue chemokine; 
MDC, macrophage-derived chemokine; STCP, stimulated T-cell chemotactic protein; MPIF, myeloid 
progenitor inhibitory factor; TECK, thymus-expressed chemokine; CTACK, cutaneous T cell-attracting 
chemokine; ILC, interleukin 11 receptor alpha-locus chemokine; ESkine, embryonic stem cell chemokine; 
ALP, amino-terminal alanine-leucine-proline chemokine; KC, JE, I-309, MARC, abcd-1, ATAC, derived from 
gene names; TMD, transmembrane domain.   
 
 
